

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
APPLICATION FOR UNITED STATES LETTERS PATENT

Title:

**METHOD OF TREATING PARKINSON'S DISEASE IN HUMANS BY INTRAPUTAMINAL  
INFUSION OF GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR**

Steven S. Gill

2 Chatford Cottages  
Litfield Road, Bristol  
England BS8 3LL  
Citizenship: Great Britain

Donald M. Gash

2106 Bahama Road  
Lexington, Kentucky 40509  
United States of America  
Citizenship: USA


Greg Allen Gerhardt

105 Parker Lane  
Nicholasville, KY 40356  
United States of America  
Citizenship: USA

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 233 437 704 US, in an envelope addressed to: MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 23, 2004

Signature:



(Richard Zimmermann)

**METHOD OF TREATING PARKINSON'S DISEASE IN HUMANS BY  
INTRAPUTAMINAL INFUSION OF GLIAL CELL-LINE DERIVED  
NEUROTROPHIC FACTOR**

5           This application claims the benefit of U.S. Provisional Application No. 60,449,789, filed February 24, 2003, which is hereby incorporated by reference in its entirety.

**FIELD OF THE INVENTION**

10           The present invention relates generally to the field of neurobiology. More particularly, it concerns methods for treating Parkinson's disease in humans and related methods of restoring atrophic dopaminergic neurons and protecting dopaminergic neurons at risk of degeneration are also described.

15                           **BACKGROUND OF THE INVENTION**

          Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive death of selected populations of dopaminergic neurons, particularly within the pars compacta of the substantia nigra, with resulting reduction in striatal dopamine levels. There are approximately 500,000  
20   specialized dopaminergic cells in the pars compacta of the substantia nigra of young adults. Symptoms of parkinsonism emerge when 75-80% of the dopaminergic innervation is destroyed. The consequential cardinal features, upon which clinical diagnosis is based, are tremor, rigidity, and akinesia/bradykinesia (Lang and Lozano, 1998). There are reportedly more than 1 million affected  
25   individuals in North America (Lang and Lozano, 1998), and an estimated overall prevalence within Europe of 1.6 per 100 population aged 65 years or older (de Rijk *et al.*, 1997). Mortality among affected individuals is 2 to 5 times greater than among their age-matched, unaffected peers (Bennett *et al.*, 1996; Morens *et*

*al.*, 1996; Louis *et al.*, 1997), and life expectancy is markedly reduced (Morens *et al.*, 1996). The single most consistent risk factor for the disease is age, and given the changing demography of industrialized nations, its burden upon their societies is likely to increase. Orally administered L-dopa, the immediate precursor of

5 dopamine that is absorbed through the small intestine and is able, unlike dopamine itself, to cross the blood-brain barrier, remains the most effective treatment when combined with an aromatic amino acid decarboxylase inhibitor, currently widely available for Parkinson's disease (Koller, 2000; Jankovic, 2002). Although L-dopa does relieve the symptoms of PD (indeed, responsiveness to it, exhibited

10 by more than 90% of patients, is one of the characteristic features of the disease [Lang and Lozano, 1998]), its use is not without problems. Its principal limitation, shared by dopamine agonists and more clearly apparent after several years of treatment, is the increasing inconsistency of patient responsiveness, manifested by motor fluctuations that take the form of distinct "wearing-off" and

15 "on-off" phenomena (Nutt and Holford, 1996; Lang and Lozano, 1998; Koller, 2000; Jankovic, 2002). "Wearing-off," also described as "end of dose deterioration," is the term given to the relatively gradual and predictable decline in response to a dose of L-dopa that occurs over time, and this contrasts with "on-off" fluctuations in motor performance that are not clearly related to L-dopa

20 dosing. In their early stages, motor fluctuations may be mitigated by approaches that prolong the actions of L-dopa (e.g., slow release formulations of the molecule or the co-administration of a catechol-*O*-methyltransferase inhibitor) or by the use of longer-acting synthetic dopamine agonists; however, these interventions cannot prevent an eventual increased unpredictability and lessened control of motor

25 fluctuations and an increased incidence of dyskinesias during "on" periods (Lang and Lozano, 1998; Koller, 2000; Jankovic, 2002).

Neurotrophic factors are target-tissue-secreted molecules required for the development, guidance, and maintenance of innervating neurons. Specific retrograde transport to the neuronal soma is the hallmark of neuronal responsivity

30 to a distinct neurotrophic factor (Oppenheim, 1989; 1991). Each neurotrophic

factor affects the development and maintenance of specific populations of neurons, with some neurons responding to more than 1 neurotrophic factor. Neurotrophic factors are expressed in different regions of the nervous system during different phases of development (Ernfors and Persson, 1991; Maisonpierre  
5 *et al.*, 1990; Schecterson and Bothwell, 1992). Because of their specificities, neurotrophic factors have become attractive drug candidates for the treatment of neurodegenerative diseases that affect specific populations of neurons (Olson *et al.*, 1992; Förander *et al.*, 1996; Arenas *et al.*, 1996).

Glial cell-line derived neurotrophic factor (GDNF) was first isolated from  
10 the culture medium of a rat glial cell line as a potent neurotrophic factor described as having relative specificity for dopaminergic neurons within dissociated rat embryonic midbrain cultures (Lin *et al.*, 1993; Lin *et al.*, 1994). After intracellular processing, GDNF is secreted as a glycosylated mature protein of 134 amino-acid residues. In its active form, GDNF is a disulfide-bonded  
15 homodimer of M<sub>r</sub> 32 kDa to 42 kDa (Lin *et al.*, 1993; Lin *et al.*, 1994). The human GDNF gene has been cloned, and recombinant human GDNF displaying full biologic activity has been expressed in *E. coli* (Lin *et al.*, 1993).

Based on data collected in cell culture (Lin *et al.*, 1993; Lin *et al.*, 1994; Hou *et al.*, 1996) and in rodent models of PD (Hoffer *et al.*, 1994; Bowenkamp *et al.*, 1995, Tomac *et al.*, 1995a, Kearns *et al.*, 1995), GDNF was thought to have  
20 significant therapeutic potential for the treatment of Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) (Gash *et al.*, 1996). However, important obstacles against the therapeutic application of GDNF to PD and other neurological disorders have been encountered. First, GDNF is a macromolecule  
25 that cannot pass through the blood-brain barrier, making it difficult to therapeutically deliver GDNF to the brain. Secondly, animal models are limited in their relevance to the human condition because of significant differences in the relative size of the brain. Intraventricular infusion of GDNF has, in fact, been attempted in PD patients but failed to result in therapeutic benefits. More  
30 specifically, 4 clinical studies in subjects with idiopathic PD (53 subjects; 50 of

these were enrolled in the double-blind, placebo-controlled trial, and 38 of 50 received study drug) and 2 clinical studies in subjects with ALS (24 subjects; all of these were enrolled in the double-blind, placebo-controlled trial). In these studies, GDNF delivered to the cerebral ventricles (ICV) by monthly bolus dose  
5 (25 to 4000 µg per dose) or by chronic infusion (3 to 50 µg/day) failed to demonstrate clinical efficacy, i.e., no clinically or statistically significant improvements in signs or symptoms of PD or ALS were observed. Furthermore, almost all subjects (92% to 100%) experienced at least one adverse event during the studies. Mild-to-moderate nausea was the most frequently reported adverse  
10 event (approximately 70% to 90% incidence across all studies). Mild-to-moderate paresthesia was reported in 30% to 80% of subjects across all studies. Weight loss was reported in 14% to 63% of subjects across all studies. Serious adverse events were reported in 21% to 44% of subjects across all studies.

Another seemingly promising approach to treating PD that failed in  
15 clinical trials was the implantation of embryonic dopaminergic neurons into the brains of patients with PD. In a randomized, double-blind trial in which patients either received intraputaminar transplants of cultured embryonic mesencephalic tissue or were given sham surgery in which the dura mater was not penetrated, no clinical improvement was observed as a result of the transplants in patients over  
20 60 years of age at one year after surgery, and only moderate improvement was apparent in those aged 60 years or less (Freed, C. *et al.*, 2001). During continued follow-up of 12 to 36 months in patients who had received transplants, dystonia and dyskinesias had developed in a number of patients, all of whom had been < 60 years of age at the time of surgery and each of whom had experienced clinical  
25 improvement during the first year after transplantation. Investigators in this study later reported findings that suggest that unbalanced increases in dopaminergic function resulted in the undesirable outcomes of neuronal transplantation for parkinsonism (Ma, Y. *et al.*, 2002).

Renewed interest in ablative neurosurgical techniques has arisen as a  
30 consequence of increased understanding of the pathophysiology of basal ganglia

and refinements in neurosurgical operating procedures, and pallidotomy and thalamotomy are again widely accepted options for consideration once a patient's condition has become increasingly difficult to manage using medication alone (Lang and Lozano, 1998; Jankovic, 2002). Regardless of the success or otherwise of such techniques to date, however, by their very nature, any side effects resulting from such interventions may very likely be irreversible. An alternative, less-irrevocable approach that simulates lesional effects, is deep-brain stimulation (DBS). In this procedure, electrical stimulation is provided on a long-term basis through implanted deep-brain electrodes and appears to result in improvements in motor function similar to those observed with ablative lesions. The mechanism by which this improvement occurs is not well understood but may involve the inhibition or disruption of neuronal activity (Lang and Lozano, 1998). However, DBS is neither neuroprotective nor neurorestorative and therefore does not halt the continual loss of remaining dopamine neurons or regenerate dopaminergic neurons already lost.

No satisfactory method exists to prevent or repair the damage caused by neuropathies, such as Parkinson's disease (parkinsonism) in human patients. Consequently, there continues to exist a long-felt need for safe and effective methods for the treatment and prevention of PD in humans. Ideally, such methods will stop the progression of the degenerative disease and even promote regeneration of the damaged neurons, without severe adverse side effects. Accordingly, it is an object of the present invention to provide such methods of treating PD in humans comprising the chronic, intraputaminal infusion of GDNF. This and other such objectives will be readily apparent to the skilled artisan from this disclosure.

## SUMMARY OF THE INVENTION

A first aspect of the present invention concerns a method of treating Parkinson's disease in a human comprising administering a pharmaceutical composition comprising a pharmaceutically effective dose of a glial cell line-

derived neurotrophic factor (GDNF) protein product to one or both putamen of a human PD patient in need thereof. The GDNF protein product includes, without limitation, a pharmaceutically effective dose of r-metHuGDNF (a dimeric protein having an the amino acid sequence shown below in Table 1) or variants and/or derivatives thereof. The invention is based on the surprising discovery that continuous delivery of r-metHuGDNF to one or both putamen of a PD patient by means of an implantable pump and one or more indwelling catheters results in dramatic anti-parkinsonian and anti-dyskinetic effects which are further associated with impressive re-innervation and/or restoration of dopamine stores in previously dopamine deficient neurons in both non-human primate models of PD and human patients afflicted with PD. The methods of the present invention are contemplated to restore neural cell function in a patient having Parkinson's disease.

Furthermore, the methods described herein are useful in repairing neural pathways damaged by Parkinson's disease in humans. Specifically, the methods described herein are capable of stimulating nerve regeneration, including re-innervation of damaged human brain tissue by dopaminergic neurons. In a preferred embodiment there is provided a method of increasing the function of dopaminergic neurons that comprises administering a pharmaceutically effective dose of r-metHuGDNF to one or both putamen of a human patient in need thereof.

Additionally provided are methods of treating cognitive disorders in humans that comprise administering a pharmaceutical composition comprising a pharmaceutically effective dose of a GDNF protein product to one or both putamen of a human in need thereof.

In still other embodiments of the present invention methods that comprise administering a pharmaceutical composition comprising a pharmaceutically effective dose of a GDNF protein product to one or both putamen of a human in need thereof may further comprise the step of assessing dopaminergic function in the brain of said human pre-operatively, and, optionally, assessing dopaminergic function in the brain of said human post-operatively at least once.

The methods of administering the GDNF to one or both putamen disclosed herein are contemplated as providing a prophylactic function in humans.

Prophylactic administration may have the effect of preserving dopaminergic neural cell function in a human having, or at risk of having, Parkinson's disease.

- 5 According to the invention, r-metHuGDNF administration to the human putamen is contemplated to preserve the integrity of the nigrostriatal pathway in the human brain. Accordingly, another embodiment of the present invention is a method of preventing degeneration of the nigrostriatal neuronal pathway or the loss of functional dopaminergic activity that comprises administering a pharmaceutical composition comprising a pharmaceutically effective dose of a GDNF protein
- 10 product to one or both putamen of a human.

### BRIEF DESCRIPTION OF THE DRAWINGS

- Figures 1(a)-(b) depict graphs of the behavioral response to daily infusions of r-metHuGDNF or vehicle. (a) Only the r-metHuGDNF recipients showed a
- 15 significant and sustained behavioral improvement in their parkinsonian features of up to 3.5 points during the treatment period. (b) In the r-metHuGDNF recipients, consistent improvements of up to 60% were evident in bradykinesia, rigidity, balance and posture at peak effect. \* $P < 0.05$  vs baseline, same animals. LL,
- 20 Lower limbs; UL, Upper limbs; T, Tremor.

- Figures 2(a)-(i) depict graphs of the striatal levels of dopamine, HVA and DOPAC. As seen in the vehicle recipients, MPTP administration markedly reduced the levels of dopamine, HVA and DOPAC (a-i) in the medial (Med), intermediate (Int) and lateral (Lat) thirds of the right striatum (see j). In contrast,
- 25 dopamine and DOPAC levels were significantly increased 233% and 180%, respectively, in the medial striatum on the lesioned right side of the r-metHuGDNF recipients (a, d). HVA levels were elevated 72%, 70% and 73% in the left medial, intermediate and lateral striatum, respectively (g-i). Values are



expressed as ng/g wet weight of tissue.  $*P < 0.05$ , r-metHuGDNF vs vehicle same side. Acb, accumbens; Cd, caudate nucleus; LV, lateral ventricle; Put, putamen.

Figures 3(a)-(j) illustrates the qualitative analysis of striatal dopamine fibers expressing TH. As seen in the low power (left panel) and high power (right panel) photomicrographs of vehicle recipients, the unilateral carotid artery infusion of MPTP virtually eliminated dopaminergic TH+ fibers in the right striatum (a, b, f, g). In comparison, chronic infusion of r-metHuGDNF stimulated TH+ fibers in the periventricular region of the right striatum (h, i, j). In one animal, the ventricular infusion of r-metHuGDNF greatly stimulated TH+ fibers in the caudate nucleus (arrows). The catheter tract is shown by an asterisk (\*). The scale bars indicate 2mm or 0.05mm in distance. Cd, caudate; LV, ventricle; Put, putamen; R, right side.

Figure 4 depicts a graph of the quantitative analysis of striatal dopamine fibers expressing TH. While a few residual TH+ fibers could be quantified in the right striatum of vehicle recipients, there was a significant five-fold increase in TH+ fibers in the periventricular striatal region of animals receiving r-metHuGDNF. TH+ fibers were most evident along the ventricular border of the right striatum, and gradually faded in a gradient from the ventricle to deeper into the parenchyma. One r-metHuGDNF recipient (#224s) was excluded from the analysis due to problems with sectioning of the tissue.  $*P < 0.05$ , r-metHuGDNF vs vehicle right side.

Figure 5(a) and 5(b) depicts patient assessments made using validated quality of life questionnaires: the 39-item Parkinson's Disease Questionnaire (PDQ 39; Figure 5(a)) and the 36-item Medical Outcomes Study short form health survey (SF-36; Figure 5(b)) before surgery and after 3, 6, 12, 18, and 24 months of chronic GDNF infusion.

Figure 6(a) and 6(b) depicts the UPDRS scores for patients at 0, 3, 6, 12, 18, and 24 months following r-metHuGDNF infusion.

## **DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS**

This invention is based on the discovery that continuous delivery of GDNF directly to one or both putamen by means of an implantable pump and at least one  
5 indwelling catheter in both non-human primate models of PD and human PD patients results in surprisingly dramatic anti-parkinsonian and anti-dyskinetic effects which are associated with impressive re-innervation and restoration of dopamine stores in previously dopamine deficient neurons.

In a primate model of PD, GDNF was administered by continuous infusion  
10 (both intraventricular and intraparenchymal) to achieve a magnitude of improvement in 3 cardinal features of PD—bradykinesia, rigidity, and postural stability—greater than that seen in studies using bolus administration. In a study in 13 female adult rhesus monkeys with neural deficits modeling the terminal stages of PD, the chronic infusion of 5 or 15  $\mu\text{g/day}$  r-metHuGDNF into the  
15 lateral ventricle or the striatum, using programmable pumps, promoted restoration of the nigrostriatal dopaminergic system and significantly improved motor functions. The functional improvements were associated with pronounced upregulation and regeneration of nigral dopamine neurons and their processes innervating the striatum. In addition, chronic r-metHuGDNF treatment did not  
20 induce the side-effects generally associated with chronic administration of L-dopa. These findings are consistent with a regenerative effect of r-metHuGDNF on dopaminergic neurons in the nigrostriatal pathway, an effect that was not observed after monthly ICV bolus administration of r-metHuGDNF.

Furthermore, five patients with PD receiving r-metHuGDNF delivered  
25 directly into the putamen for two years showed a 57% improvement in the off-medication motor sub-score of the Unified Parkinson's Disease Rating Scale (UPDRS) and 63% improvement in the activities of daily living sub-score. Medication induced dyskinesias were reduced by 60% and were not seen off medication during chronic r-metHuGDNF delivery.

<sup>18</sup>F-dopa PET showed a significant 28% increase in dopamine storage in the putamen at 18 months suggesting a direct effect of r-metHuGDNF on dopamine function. Repeated measures analysis of variance (MANOVA) identified a significant difference in the <sup>18</sup>F-dopa uptake constant (K<sub>i</sub>) between the

5 baseline scan and all post-operative scans in the posterior putamen (p<0.001). The increase was most marked at 24 months (60%, p<0.001).

Accordingly, a uniquely effective and long needed method of treating or preventing the pathological hallmarks of Parkinson's disease in humans as well as the devastating symptoms of PD is provided by the present invention.

10 The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

### Abbreviations

In the preceding description and the experimental disclosure which follows, the following abbreviations apply:

6-OHDA	6-hydroxydopamine
ALS	amyotrophic lateral sclerosis
ASA	acute systemic anaphylaxis
AUC	area under the concentration vs time curve
CAPIT	Core Assessment Program for Intracerebral Transplantations
CAPS	3-(cyclohexylamino)-1-propanesulfonic acid
CHO	Chinese hamster ovary
CI	continuous infusion
CSF	cerebrospinal fluid
CT	computed tomography
DA	dopamine, dopaminergic
DOPAC	<i>3,4-dihydroxyphenylacetic acid</i>
<i>E. coli</i>	<i>Escherichia coli</i>
FCA	Freund's Complete Adjuvant
GDNF	glial cell line-derived neurotrophic factor
GLP	Good Laboratory Practice
HPLC	high-performance liquid chromatography

HVA	homovanillic acid
ICV	intracerebroventricular
IM	intramuscular
ISN	intranigral
IT	intrathecal
IV	intravenous
L-dopa	3,4-dihydroxyphenylalanine (levodopa)
r-metHuGDNF	recombinant-methionyl human GDNF
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
PD	Parkinson's disease
PET	positron-emission tomography
pmn	progressive motor neuropathy
Ret	receptor tyrosine kinase
r-metHuGDNF	recombinant-methionyl human GDNF
SC	subcutaneous
SDS-PAGE	sodium dodecylsulfate-polyacrylamide gel electrophoresis
SEM	standard error of the mean
TGF	transforming growth factor
TH	tyrosine hydroxylase
TH+	tyrosine hydroxylase positive
UPDRS	Unified Parkinson's Disease Rating Scale

## Definitions

Unless otherwise noted, technical terms are used according to conventional usage. As utilized in accordance with the present disclosure, the following terms  
5 shall be understood to have the following meanings:

As used herein, the term "catheter" refers to any tubular medical device for insertion into a cavity, tissue, organ, or any substructure thereof of a living mammal to permit injection of a therapeutic agent. As particularly used here, a catheter is used to deliver r-metHuGDNF to the brain or substructures thereof  
10 such as the putamen. An "indwelling" catheter is one that is implanted and left in place for protracted periods, such as fifteen minutes or longer.

As used herein, the phrase "catheter system" refers to the combination of at least one catheter and at least one accessory device including, but not limited to, an anchor, stylet, guide tube, guide wire or a combination thereof.

"Continuous delivery" or "chronic infusion" are interchangeable and are intended to mean delivery of a substance over a period of time such that the procedure is distinguished from "bolus" delivery. Continuous delivery generally involves the delivery of a substance over a period of time without interruption. The rate of delivery need not be constant, and the period of delivery need not be very long, i.e., the period of constant delivery may be over a period of maybe half an hour or an hour or a few hours, but may also be over a period of days, weeks, months, or even years.

"Admixing" as used herein denotes the addition of an excipient to a polypeptide of interest, such as by mixing of dry reagents or mixing of a dry reagent with a reagent in solution or suspension, or mixing of aqueous formulations of reagents.

"Excipient" as used herein denotes a non-therapeutic agent added to a pharmaceutical composition to provide a desired consistency or stabilizing effect.

"Implanted" means placed within the body, and maintained at that location for some extended period of time. As used herein it is intended that the period of time during which the implanted object is maintained in place will be, in general, considerably greater than that customarily required to introduce a bolus of a substance, such as a drug. For example, a catheter used in a method of the invention may be placed within a tissue or organ such that the catheter so implanted is intended to remain at the site of implantation for some extended period of time. Some of the drug delivery apparatuses that may be used in the methods of the invention, for example the drug pumps and/or catheters, are designed to be implanted for periods greater than a month and even years and to deliver drug during this period. A drug delivery apparatus may be implanted, for example, subcutaneously, or within a tissue or organ, or within a body cavity such as the peritoneal cavity, infraclavicular space, , the thoracic cavity, the pelvic cavity, or any other cavity or location that is convenient for delivery of the

intended substance. A catheter may be implanted into a tissue, for example into brain tissue, and may be affixed in place by fixing the catheter to another tissue, such as bone, e.g., the skull, or cartilage, using an adhesive or screws, clamps, sutures or any other suitable fixing means.

5           The phrases “dopaminergic dysfunction”, “dopaminergic dysregulation”, “dopaminergic degeneration”, “dopamine depleted”, “dopamine deficient”, or grammatical equivalents thereof, may be used interchangeably herein. All such phrases are intended to encompass at least one of the following conditions or disorders: Parkinson’s disease, neuronal dopamine deficit, dopaminergic neuron  
10 deficit, dopaminergic neuron lesions, hypo-dopaminergic innervation, dopamine synthesis incapacity, dopamine storage incapacity, dopamine transport incapacity, or dopamine uptake incapacity. Dopaminergic dysfunction can be evidenced by analyzing factors including, but not limited to, the following: 1) the number of TH expressing neurons 2) size of dopamine neuronal cells 3) dopamine metabolite  
15 levels 4) dopamine uptake, 5) dopamine transport, 6) neuronal dopamine uptake, 7) dopamine transporter binding, 8) quantal size of terminal dopamine release, 9) rate of dopamine turnover, 10) TH+ cell count, 11) TH+ innervation density and 12) TH+ fiber density.

          The phrase “target site”, or a grammatical version thereof, refers to the site  
20 for intended delivery of a substance, such as a drug. In particular embodiments of the present invention, a preferred target site is an area of dopaminergic degeneration or dopaminergic dysfunction within the brain of a human afflicted with Parkinson’s disease. More preferably, the target site is the central area of the putamen. Even more preferably, the target site is the posterior area of the  
25 putamen. Most preferably, the target site is the postero-dorsal area of the putamen. Furthermore, a particular target site may be targeted unilaterally or bilaterally with respect to the hemispheres of the brain.

          “Proximal end” is a relative term, and generally refers to the end of a device, such as a catheter that is nearest to the operator (i.e., the surgeon) and is  
30 furthest away from the treatment site. In the present invention a catheter has a

proximal end that may be communicably attached to an access port or drug delivery apparatus, such as a pump, or reservoir.

“Tyrosine hydroxylase-positive” or “TH+” is intended to refer to the presence of tyrosine hydroxylase in a referenced nervous tissue as indicated by the results from any technique known in the art as a means to detect and/or measure tyrosine hydroxylase, tyrosine hydroxylase encoding mRNA, or tyrosine hydroxylase activity.

“Distal end” is a relative term and generally refers to the end of a device, such as a catheter, that is furthest away from the operator (i.e., the surgeon) and is closest to the treatment site. In the present invention the distal end of a catheter may be communicably attached to an opening that allows for the delivery of drug to the target site.

“Drug delivery apparatus” as used herein includes but is not limited to, a drug reservoir and/or a drug pump of any kind, for example an osmotic pump, an electromechanical pump, an electroosmotic pump, an effervescent pump, a hydraulic pump, a piezoelectric pump, an elastomeric pump, a vapor pressure pump, or an electrolytic pump. Preferably, such a pump is implanted within the body.

Throughout this specification, reference to the term “GDNF” or the phrase “GDNF protein product” or “GDNF polypeptide”, all of which are used interchangeably, refers to glial cell line-derived neurotrophic factor from any species, including murine, bovine, ovine, porcine, equine, avian, and preferably human, in native sequence or in genetically engineered variant form, including, without limitation, biologically active fragments, analogs, variants, (including, insertion, substitution, and deletion variants) and derivatives thereof, and from any source, whether natural, synthetic, or recombinantly produced.

Exemplary GDNF polypeptides useful in the present invention include, without limitation, any of GDNF protein products described in U.S. patent Nos. 5,731,284, 6,362,319, 6,093,802, and 6,184,200 (all of which are hereby incorporated by reference in their entireties). Preferred GDNF protein products

for use in the methods of the present invention include, but are not limited to, r-metHuGDNF, a recombinant GDNF protein produced in *E coli* which has an amino acid sequence identical to native mature human GDNF with the addition of an amino terminal methionine. Thus, r-metHuGDNF consists of 135 amino acids.

- 5 Seven of the amino acids are cysteines, which are involved in one intermolecular disulfide bond and three intramolecular disulfide bonds. In its active form, r-metHuGDNF is a disulfide-bonded homodimer. The primary amino acid sequence of monomeric r-metHuGDNF is provided in Table 1.

**Table 1. Primary Amino Acid Sequence of r-metHuGDNF**

Primary Amino Acid Sequence											Amino Acid No.
H <sub>2</sub> N-Met	Ser	Pro	Asp	Lys	Gln	Met	Ala	Val	Leu	Pro	10
	Arg	Arg	Glu	Arg	Asn	Arg	Gln	Ala	Ala	Ala	20
	Ala	Asn	Pro	Glu	Asn	Ser	Arg	Gly	Lys	Gly	30
	Arg	Arg	Gly	Gln	Arg	Gly	Lys	Asn	Arg	Gly	40
	Cys	Val	Leu	Thr	Ala	Ile	His	Leu	Asn	Val	50
	Thr	Asp	Leu	Gly	Leu	Gly	Tyr	Glu	Thr	Lys	60
	Glu	Glu	Leu	Ile	Phe	Arg	Tyr	Cys	Ser	Gly	70
	Ser	Cys	Asp	Ala	Ala	Glu	Thr	Thr	Tyr	Asp	80
	Lys	Ile	Leu	Lys	Asn	Leu	Ser	Arg	Asn	Arg	90
	Arg	Leu	Val	Ser	Asp	Lys	Val	Gly	Gln	Ala	100
	Cys	Cys	Arg	Pro	Ile	Ala	Phe	Asp	Asp	Asp	110
	Leu	Ser	Phe	Leu	Asp	Asp	Asn	Leu	Val	Tyr	120
	His	Ile	Leu	Arg	Lys	His	Ser	Ala	Lys	Arg	130
	Cys	Gly	Cys	Ile	COOH						134

10

The GDNF protein products useful in the present invention may be isolated or generated by any means known to those skilled in the art. Preferably, GDNF is recombinantly produced. In a preferred method, the GDNF is cloned and its DNA expressed, e.g., in mammalian cells or bacterial cells. Exemplary

15 methods for producing GDNF protein products useful in the present invention are described in U.S. Pat. No. 6,362,319, 6,093,802 and 6,184,200 (all of which are hereby incorporated by reference in their entireties).



GDNF pharmaceutical compositions typically comprise a therapeutically effective amount of at least one GDNF protein product and one or more pharmaceutically and physiologically acceptable formulation agents. Suitable formulation agents include, but are not limited to, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, vehicles, diluents, excipients and/or pharmaceutical adjuvants. For example, a suitable vehicle may be, physiological saline solution, citrate buffered saline, or artificial CSF, possibly supplemented with other materials common in compositions for parenteral administration.

Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Those skilled in the art would readily recognize a variety of buffers that could be used in the compositions, and dosage forms used in the invention. Typical buffers include, but are not limited to pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. Preferably, the buffer components are water soluble materials such as phosphoric acid, tartaric acids, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof.

The primary solvent in a vehicle may be either aqueous or non-aqueous in nature. In addition, the vehicle may contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. A preferred pharmaceutical composition of GDNF comprises a therapeutically effective amount of at least one GDNF protein and a pharmaceutically acceptable vehicle. More preferably, the pharmaceutically acceptable vehicle is an aqueous buffer. More preferably, the vehicle comprises sodium chloride at a concentration of about 100 mM to about 200 mM and sodium citrate at a concentration of about 5 mM to about 20 mM. Even more preferably, the vehicle comprises sodium chloride at a concentration of about 125 mM to about 175 mM and sodium citrate at a concentration of about 7.5 mM to about 15 mM. Even more preferably, the vehicle comprises sodium chloride and sodium citrate at a concentration of about 150 mM and about 10 mM, respectively. Most preferably, the GDNF

pharmaceutical composition is formulated as a liquid with 10 mM sodium citrate and 150 mM sodium chloride at a pH of 5.0.

The pharmaceutical composition may contain still other pharmaceutically-acceptable formulation agents for modifying or maintaining the rate of release of GDNF protein product. Such formulation agents are those substances known to artisans skilled in formulating sustained release formulations. For further reference pertaining to pharmaceutically and physiologically acceptable formulation agents, see, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712 (the disclosure of which is hereby incorporated by reference).

Once the therapeutic composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready to use form, a lyophilized form requiring reconstitution prior to use, or a liquid form requiring dilution prior to use. Preferably, the GDNF pharmaceutical composition is provided in sterile single-use vials at a concentration of 10 mg/mL and stored frozen at a temperature of  $-2-8^{\circ}\text{C}$  until use. Immediately prior to administration, the GDNF protein product should be thawed and appropriately diluted with a sterile citrate buffered saline (pH 5.0) consisting of 150 mM sodium chloride and 10 mM sodium citrate.

In the methods of the present invention, GDNF is chronically administered to a site of dopaminergic dysfunction in the human brain by means of an implantable pump and one or more catheters. Preferably, the region of a PD patient's brain targeted for chronic delivery of GDNF is determined by assessing biomarkers of PD disease or disease progression including, but not limited to, the number of TH expressing neurons 2) size of dopamine neuronal cells 3) dopamine metabolite levels 4) dopamine storage, 5) dopamine transport, 6) neuronal dopamine uptake, 7) dopamine transporter binding, 8) quantal size of terminal dopamine release, 9) rate of dopamine turnover, 10) TH+ cell count, 11) TH+ innervation density and 12) TH+ fiber density. Even more preferably, GDNF is

chronically infused directly into a region of the human brain which is severely dopamine depleted. Even more preferably, the region of a PD patients brain which is severely dopamine depleted and, therefore, targeted for chronic delivery of GDNF is determined by neuroimagery of the brain, or regions thereof. Even  
5 more preferably, the neuroimagery technique used to determine the site of chronic infusion of GDNF is selected from the group consisting of  $^{18}\text{F}$ -fluorodopa positron emission tomography ( $^{18}\text{F}$ -dopa PET) <sup>13</sup> and  $^{123}\text{I}$ -2 $\beta$ -carboxymethoxy-3 $\beta$ -(4-iodophenyl)tropane uptake on single-photon emission tomography ( $^{123}\text{I}$ - $\beta$ -CIT SPECT). In an even more preferred embodiment of the present invention,  
10 GDNF is chronically infused directly into at least one dopaminergic dysfunctional putamen of a PD patient. Even more preferably, GDNF is chronically infused directly into the posterior region of at least one dopaminergic dysfunctional putamen of a PD patient. Most preferably, GDNF is chronically infused directly into at least one dopaminergic dysfunctional postero-dorsal putamen of a PD  
15 patient.

A number of drug delivery apparatus, catheters, catheter systems and combinations thereof have been developed for the dispensing of medical substances to specific sites within the body and are all readily available to those skilled in the art for use in the methods of the present invention. Therefore, one  
20 may use prior art drug delivery devices, catheters, and catheter systems for delivering the GDNF compositions to the target site of the brain of the patient at specified concentrations and/or at specified times and/or at different delivery rates. By way of illustration and not limitation, in the methods of the present invention one may use the technology described in U.S. Patent Publication No.  
25 US20030120262, US20030208184, or US20030225372 or U.S. Patent No. 4,931,050, 4,838,887, 5,207,666, 4,714,462, 5,176,641; 3,923,060, 4,003,379, 4,588,394, 4,447,224, 5,575,770, 4,978,338, 5,908,414, 5,643,207, 6,589,205 or 6,592,571. The entire disclosure of each of these U.S. Patent Applications and U.S. Patents is hereby incorporated by reference into this specification. A  
30 preferred drug delivery apparatus useful in the context of the present invention includes one described in U.S. Patent No. 5,752,930 or U.S. Patent Application

No. US20030216714 (which are hereby incorporated by reference in their entireties). A more preferred drug delivery apparatus useful in the context of the present invention includes one described in U.S. Patent No. 6,620,151 (which is hereby incorporated by reference in its entirety). An even more preferred drug  
5 delivery apparatus useful in the context of the present invention includes one described in U.S. Patent Application No. US20030216714 (which is hereby incorporated by reference in its entirety). Most preferably the drug delivery apparatus used in the context of the present invention is one described in U.S. Pat. Nos. 4,146,029, 4,013,074, or 4,692,147, (which are hereby incorporated by  
10 reference in their entireties) commercial embodiments thereof including, but not limited to, the Synchromed® I, Synchromed® EL, and Synchromed® II infusion pumps (Medtronic, Inc., Minneapolis, Minn.).

In another embodiment of the present invention, in conjunction with any of the above or below embodiments, a number of catheters and catheter systems have  
15 been developed for the dispensing of agents, such as drugs, to specific sites in the body and are readily available to those skilled in the art for use in the methods of the present invention. By way of illustration and not limitation, in the methods of the present invention one may use the technology described in U.S. Patent Publication No. 20030216700, 20030199831, or 20030199829 or U.S. Patent No.  
20 6,319,241. The entire disclosure of these U.S. Patent Applications and the United States patent is hereby incorporated by reference into this specification. A preferred catheter or catheter system useful in the context of the present invention includes, but is not limited to, an intraparenchymal infusion catheter or catheter system described in International Patent Application Publication No: WO  
25 02/07810 or WO03/002170 or U.S. Patent No. 5,720,720, 6,551,290 or 6,609,020. The entire disclosure of each of these Patent Applications and United States patents is hereby incorporated by reference into this specification. An even more preferred catheter or catheter system useful in the context of the present invention includes, but is not limited to, an intraparenchymal infusion catheter or catheter  
30 system described in International Patent Application Publication No: WO 03/077785 (which is hereby incorporated by reference in its entirety). A most

preferred catheter or catheter system useful in the context of the present invention is an intraparenchymal infusion catheter or catheter system described in U.S. Patent No. 6,093,180 (which is hereby incorporated by reference in its entirety).

In another embodiment of the methods of the present invention, in  
5 conjunction with any of the above or below embodiments, a therapeutically effective dose of GDNF is chronically infused directly into one or both putamen of a human PD patient. The phrase “therapeutically effective dose” or “pharmaceutically effective dose”, which are used interchangeably herein, refers to that amount of GDNF sufficient to result in any amelioration, impediment,  
10 prevention or alteration of any biological symptom generally associated with a neurodegenerative disorder including, without limitation, PD by one skilled in the relevant art. In a preferred embodiment of the present invention, in conjunction with any of the above or below embodiments, GDNF is chronically infused directly into a human putamen at a dose of about 1 µg/putamen/day to about 100  
15 µg/putamen/day. More preferably, GDNF is chronically infused directly into a human putamen at a dose of about 5 µg/putamen/day to about 50 µg/putamen/day. Even more preferably, GDNF is chronically infused directly into a human putamen at a dose of about 10 µg/putamen/day to about 75 µg/putamen/day. Even more preferably, GDNF is chronically infused directly into a human putamen at a  
20 dose of about 15 µg/putamen/day to about 50 µg/putamen/day. Even more preferably, r-metHuGDNF is chronically infused directly into human putamen at a dose of about 20 µg/putamen/day to about 40 µg/putamen/day. Even more preferably, r-metHuGDNF is chronically infused directly into a human putamen at a dose of about 25 µg/putamen/day to about 30 µg/putamen/day. Even more  
25 preferably, r-metHuGDNF is chronically infused directly into a human putamen at a dose of about 15 µg/putamen/day to about 30 µg/putamen/day. Most preferably, r-metHuGDNF is chronically infused directly into a human putamen at a dose of about 25 µg/putamen/day to about 30 µg/putamen/day.

The inventive method has the effect, upon application to parkinsonian  
30 patients, of significantly reducing symptoms of Parkinson's disease, the resulting

improved condition of the patient continuing for at least 30 months. In particular, a clear improvement of disease-specific symptoms was obtained with the inventive method insofar as motoricity, fine motoricity, and fine dexterity. In addition, mobility and concentration power was increased and reaction time was  
5 decreased. Pronunciation, facial expressiveness, posture, sense of smell, libido, sexual function, and emotional condition were improved and state of mind was brightened.

In yet another embodiment of the present invention, GDNF can be used as a cognitive enhancer, to enhance learning, particularly as a result of dementias or  
10 trauma, or to inhibit cognitive decline and/or dementia, for example, in patients with PD. Alzheimer's disease, which has been identified by the National Institutes of Aging as accounting for more than 50% of dementia in the elderly, is also the fourth or fifth leading cause of death in Americans over 65 years of age. Four million Americans, 40% of Americans over age 85 (the fastest growing segment  
15 of the U.S. population), have Alzheimer's disease. Twenty-five percent of all patients with Parkinson's disease also suffer from Alzheimer's disease-like dementia. Applicants have shown here for the first time that chronic intraputaminial administration of GDNF has application in treating or preventing cognitive disorders in humans. In particular, intraputaminial administration of  
20 GDNF has application in treating or preventing cognitive disorders and/or Alzheimer's disease-like dementia associated with PD.

The present invention is also directed to kits which comprise:

(a) one or more supplies of a pharmaceutical composition comprising a GDNF protein product and a pharmaceutically acceptable  
25 vehicle, excipient, or diluent; and

(b) supplies adapted for refilling an implanted drug delivery device with said composition.

In a preferred embodiment of the kits the GDNF protein product is r-metHuGDNF. In another preferred embodiment, the kit further comprises

at least one syringe. In another preferred embodiment, the kit further comprises; and one or more supplies of a pharmaceutically acceptable diluent. More preferably, the pharmaceutically acceptable diluent is citrate buffered saline consisting of about 150 mM sodium chloride and about 10 mM sodium citrate, pH  
5 of about 4.5 to about 5.5. Even more preferably, the pharmaceutically acceptable diluent is citrate buffered saline consisting of 150 mM sodium chloride and 10 mM sodium citrate, pH 5.0. Even more preferably, the kit further comprises instructions for diluting the pharmaceutical composition with the diluent. Even more preferably, the kit further comprises instructions for refilling said drug  
10 delivery device.

In certain examples, the kit comprises multiple sealed containers, including, but not limited to, removable sealed containers that contain the pharmaceutical composition, diluent, or supplies provided for refilling an implanted drug delivery device with said composition. Several containers may  
15 contain the same provision. Furthermore, a container may contain more than one provision.

Preferably, the pharmaceutical compositions, diluents, and supplies provided for refilling an implanted drug delivery device with the GDNF pharmaceutical composition are provided sterile in sealed containers in the kit.

20 In some embodiments of the kit, the pharmaceutical composition is provided in powder or other dry form. The powder or other dry form may be combined with a liquid, including, without limitation, the diluent for purposes of reconstituting the pharmaceutical composition in a liquid form for use in refilling the implanted drug delivery device.

25

### **EXAMPLES**

The following examples, including the experiments conducted and results achieved are provided for illustrative purposes only and are not to be construed as  
30 limiting the invention.

**Example 1: Treatment of advanced parksonian like neural deficits in non-human primates with chronic, controlled r-metHuGDNF infusion into the brain.**

5           To assess the restorative actions of r-metHuGDNF under conditions where neuroprotection would have only a minor role, the late stages of human PD were modeled using rhesus monkeys with stable, advanced hemi-parkinsonian features induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Bankiewicz *et al.*, 1983; Smith *et al.*, 1993; Emborg-Knott and Domino, 1998).  
10   In this model, MPTP infusion through the right carotid artery results in an approximate 75% loss of dopamine neurons expressing the phenotypic marker tyrosine hydroxylase (TH) in the right substantia nigra and a greater than 99% depletion of dopamine in the right putamen (Gash *et al.*, 1996). These reductions are comparable with advanced human parkinsonism where cell counts typically  
15   show a 60-70% loss of nigral dopamine neurons (Jellinger, 1986) and a 99% dopamine depletion in the putamen (Kish *et al.*, 1988). Subcutaneously implanted programmable pumps connected to catheters implanted into either the right lateral ventricle adjacent to the striatum or bilaterally into the striatum were used to continuously deliver controlled doses of r-metHuGDNF or vehicle to the MPTP-  
20   injured nigrostriatal system. Behavioral recovery was quantified using standardized videotaped tests; regeneration of the nigrostriatal dopamine system was analyzed by quantitative morphology and high performance liquid chromatography (HPLC) measurements of dopamine levels. The levels of r-metHuGDNF promoting regeneration of the nigrostriatal system and motoric  
25   recovery were quantified by enzyme-linked immunosorbent assay (ELISA) and HPLC.

**Animal Procedures**

30           All procedures were conducted in the Laboratory Animal Facilities of the University of Kentucky, which are fully accredited by the Association for



Assessment and Accreditation of Laboratory Animal Care International (AAALACI). Veterinarians skilled in the health care and maintenance of nonhuman primates supervised all animal care. The University of Kentucky's Animal Use Committee approved all protocols.

- 5           Thirteen adult ( $13 \pm 0.6$  years old) female rhesus monkeys (*Macaca mulatta*) received right intracarotid artery infusions of 0.4 mg/kg MPTP to induce continuously expressed parkinsonian features (Ovadia *et al.*, 1995). The animals were monitored for a minimum of two months to ensure that the parkinsonian features expressed were stable. At this point, using stereotaxic procedures guided  
10 by magnetic resonance imaging, a catheter (1 mm O.D., Medtronic Inc., Minneapolis, MN) was surgically implanted into the right lateral ventricle adjacent to the striatum (n=8) or bilaterally into the central part of the putamen (n=5). The catheter(s) were then connected via a flexible polyurethane tubing to a programmable pump (SynchroMed™ model 8616-10; Medtronic Inc.,  
15 Minneapolis, MN) subcutaneously implanted in the lateral abdominal region (Grondin *et al.*, 2001). The catheters were implanted bilaterally into the putamen in order to parallel potential bilateral effects of the ventricular delivery on nigral neurons (Gash *et al.*, 1996). Placement of the catheter(s) was verified by magnetic resonance imaging. The animals were anesthetized with isoflurane (1-  
20 3%) during these procedures. The vehicle (10 mM citrate, 150 mM NaCl buffer) was infused daily in all thirteen animals during the first month following the surgery and continued in five control animals for an additional three months (n=3 intraventricular, n=2 intraputamenal). The remaining eight animals received infusions of nominally 7.5 µg r-metHuGDNF (Amgen, Thousand Oaks, CA) per  
25 day over the same three month period (n=5 intraventricular, n=3 intraputamenal). Four of the animals responded to this dose. In order to achieve a similar level of behavioral improvement among animals ( $\geq 2$  points on the rating scale), the daily dose was increased to nominally 22.5 µg in the other four animals (n=2 intraventricular, n=2 intraputamenal). The pumps were refilled with  
30 r-metHuGDNF or vehicle every 4 weeks by injections through the skin into a fill port (Grondin *et al.*, 2001). To estimate actual dose levels of r-metHuGDNF

chronically infused into the brain, residual r-metHuGDNF F solutions were removed from the pumps of three animals at the four, eight and twelve week time points of r-metHuGDNF infusion. Protein loss from adsorption to the pump was estimated by an ELISA essay (Amgen, Thousand Oaks, CA), while the stability of  
5 r-metHuGDNF after 4 weeks in the pumps at 37°C (body temperature) was determined by reverse phase HPLC.

Motor functions were assessed using previously published nonhuman primate parkinsonian scale, patterned after the human Unified Parkinson's Disease Rating Scale (Ovadia *et al.*, 1995). Two hours of weekly standardized tests were  
10 conducted pre- and post-treatment, and were evaluated from coded videotapes (Ovadia *et al.*, 1995). A review of this widely used approach is published elsewhere (Imbert *et al.*, 2000). In addition, the tapes were analyzed to determine if the animals displayed side effects from the treatment (Miyoshi *et al.*, 1997). Post MPTP/baseline scores were defined as the averaged scores of two  
15 videotaping sessions conducted prior to implanting the pumps. Because the rating scale is non-linear, the cumulative scores obtained weekly in the control and the r-metHuGDNF recipients were analyzed using a non-parametric Friedman test for related samples followed with a post hoc analysis by a non-parametric Wilcoxon signed rank test on pairs of related samples. For a more in depth analysis of the  
20 behavioral response to r-metHuGDNF, the rating scale was broken into its different components, namely, posture, balance, rigidity, tremor and bradykinesia. For each rated category, the post MPTP/baseline scores and the scores obtained at peak effect in the treated group, were compared using a Wilcoxon signed rank test on pairs of related samples. Each animal was used as its own control.

25 After receiving an initial dose of ketamine hydrochloride (20-25 mg/kg), the animals were deeply anesthetized using pentobarbital sodium (20 mg/kg) and transcardially perfused with heparinized ice-cold physiological saline. The brains were then recovered and cut into 4-mm-thick coronal sections using an ice-cold brain mold. Multiple brain tissue punches were taken on both sides of the brain  
30 from a single section through the caudate (10-15 punches), putamen (10 punches) and accumbens (5 punches) for dopamine, homovanillic acid (HVA) and 3,4-

dihydroxy-phenylacetic acid (DOPAC) measurements by HPLC (Cass, 1996). To assess for regional effects of r-metHuGDNF, the left and right striatum in the coronal brain section used for tissue punches were each divided into three regions of approximately 4 mm each (medial, intermediate, lateral), extending from the lateral ventricle to the lateral border of the putamen (Fig. 2j). All the punches taken in a given region were averaged, providing a single measure per region per animal for dopamine, DOPAC or HVA. For each hemisphere, independent samples t-tests were used to estimate differences in dopamine, DOPAC or HVA levels between animals in the control and r-metHuGDNF treatment groups (assuming unequal variances). Five tissue punches were also taken from a section of the globus pallidus on both sides of the brain for similar analyses.

Intact 4-mm-thick coronal striatal sections, along with the entire midbrain, were immersion-fixed in a 4% paraformaldehyde solution at 4°C and processed so that 40-μm-thick sections could be cut on a sliding knife microtome through the striatum and the substantia nigra. As described elsewhere (Gash *et al.*, 1995), the sections were further processed for immunohistochemical staining for TH (monoclonal antibody, 1:1000; Chemicon International Inc., Temecula, CA). The number and perikaryal size of TH+ midbrain dopaminergic neurons were estimated using an optical fractionator method for unbiased stereological cell counting (Gash *et al.*, 1996). The ventral tegmental area was not included in the analysis. For each hemisphere, independent samples t-tests were used to analyze the effects of r-metHuGDNF on nigral cell counts or cell size between animals in the control and r-metHuGDNF treatment groups (assuming unequal variances). In addition, a quantitative analysis of TH+ fiber density was conducted on both sides of the brain on a 40-μm-thick section of the striatum. Using the lateral ventricle as the reference point, a 1.2 x 1.2 mm grid was used to quantify (number of pixels, Bioquant Image Analysis System) the striatal section dorso-ventrally. All the data measured dorso-ventrally at a given distance from the lateral ventricle were averaged, providing a single measure per 1.2-mm-wide dorso-ventral area per animal. The data were analyzed using an analysis of variance (ANOVA) testing for a within-subject factor of distance from the lateral ventricle and a between-

subject factor of treatment group (vehicle vs. r-metHuGDNF). The ANOVA was followed by independent samples t-tests (assuming unequal variances). The initial ANOVA testing for within-subject factors of hemisphere (left vs right) and region (medial, intermediate, lateral) and between-subject factors of treatment group (vehicle vs r-metHuGDNF) and route of infusion (intraventricular vs intraputamenal) revealed no main effect for route of infusion for the following measures: TH+ fiber density, nigral cell size and number, dopamine and dopamine metabolite levels in the striatum and globus pallidus. Similarly, non-parametric Mann Whitney-U tests indicated no effect for route of infusion on the weekly behavioral scores of each treatment group. Thus, in accordance with previously published data (Gash *et al.*, 1996), all r-metHuGDNF recipients were treated as one group.  $P \leq 0.05$  was considered significant in all analyses. In addition to the mixed-group data analysis, data from each animal are presented for behavior, neurochemistry and histology.

#### **r-metHuGDNF stability and dose levels**

The nominal concentration of r-metHuGDNF in the pumps was 25  $\mu\text{g/mL}$ . In residual r-metHuGDNF solutions removed at the four, eight and twelve week time points of r-metHuGDNF infusion, r-metHuGDNF levels of 10.0, 18.3 and 14.5  $\mu\text{g/mL}$ , respectively, were measured by ELISA. Separate measurements showed that the sampling technique (adsorption to the syringe used to recover r-metHuGDNF from the pump and vials used for storage) accounted for the loss of 3.2  $\mu\text{g/mL}$  r-metHuGDNF. After adding this back to the ELISA measurements, estimated levels of r-metHuGDNF after four weeks in the pumps at 37°C ranged from 56-86% of the nominal value. Reverse phase-HPLC showed that 94% of the residual protein after four weeks in a pump eluted in the GDNF native peak, suggesting that the loss was primarily due to adsorption, with little degradation of the remaining protein. Based on average ELISA measurements of 71% of nominal levels and 94% levels of native protein, the nominal daily doses of 7.5  $\mu\text{g/day}$  and 22.5  $\mu\text{g/day}$  were estimated to conservatively represent a

minimum of 5  $\mu$ g/day and 15  $\mu$ g/day of r-metHuGDNF infused into the brain, respectively.

### **Parkinsonian features and the nigrostriatal system pre-GDNF treatment**

5           At 45 days post-MPTP administration, the animals were assigned to either r-metHuGDNF (n=8) or vehicle (n=5) test groups so that groups were comparable in their cumulative disability scores prior to catheter implantation (Fig. 1a). To better reflect the improvement in disability, the data were expressed as differences in points between the MPTP/baseline score and post-treatment scores. The  
10   parkinsonian features of all thirteen monkeys remained stable (no significant changes) from 45-60 days post-MPTP administration (time 0, Fig. 1a). The catheters were implanted at the 60-day time point. All animals recovered without incident following catheter(s) placement and no fatalities were seen during the four-month study. No significant behavioral changes were seen through the four-  
15   week period of vehicle infusion (Table 2). The parkinsonian features then continued to be expressed at the same level in the five vehicle recipients for the remaining three months of the study.

          In the vehicle-only recipients at the termination of the study, overall tissue levels of dopamine in the severely lesioned right striatum were 3% of the levels on  
20   the left side of the brain (Fig. 2), with the highest residual levels (11%) in the medial striatal region consisting of the periventricular caudate nucleus and the nucleus accumbens (Table 3). The lowest dopamine levels (<1%) were in the intermediate and lateral regions of the striatum containing the putamen. Dopamine metabolite levels, DOPAC and HVA, were also highest in the medial  
25   striatum (Table 3). MPTP also significantly decreased pallidal levels of dopamine and related metabolites in the vehicle-treated animals. When compared to tissue levels in the left pallidum, an average 80% depletion in dopamine ( $194 \pm 16$  vs  $38 \pm 7$ ), HVA ( $91 \pm 11$  vs  $20 \pm 7$ ) and DOPAC ( $9003 \pm 990$  vs  $1880 \pm 250$ ) was seen in the right pallidum of vehicle recipients.

30           The medial to lateral profile of TH+ fiber density in the right striatum of vehicle recipients mirrored dopamine levels (Figs. 3a, 3b and 4). Overall right

striatal TH+ fiber staining was 3% of levels in the left striatum. The highest fiber density levels (up to 8%) were in the striatal region directly adjacent to the ventricle, with the lowest levels (~2%) found distal to the ventricle. Consistent with the TH+ fiber reduction in the right striatum, the number of TH+ neurons in

5 the right substantia nigra of vehicle recipients was reduced to 17.5% that found on the contralateral side and the neurons were approximately 100  $\mu\text{m}^2$  smaller.

**Anti-parkinsonian effects of r-metHuGDNF infusion**

While the chronic infusion of vehicle had no effect on motor functions, a steady improvement was observed in the treated animals during the first month post r-metHuGDNF infusion, reaching an averaged 2.5 points on the rating scale (Fig. 1a). This level of behavioral improvement was thereafter maintained for two additional months, averaging 3.5 points by the end of the study. This represents an overall 36% improvement in disability. In the treated animals, consistent improvements of up to 60% were evident in bradykinesia, rigidity, balance and posture at peak effect (Fig. 1b). Rigidity was defined as decrease in limb extension and/or use (Ovadia *et al.*, 1995). The chronic infusion of r-metHuGDNF was well tolerated by all animals, as it did not induce any observable adverse effects such as dyskinesias, self-mutilation or vomiting. Body weight loss, a side effect observed with acute injections of r-metHuGDNF (Gash *et al.*, 1996), was not significant in the chronic r-metHuGDNF recipients during the 4-month study (data not shown).

**Upregulation of the nigrostriatal dopaminergic system post-GDNF treatment**

In comparison to the vehicle recipients, dopamine and its metabolite DOPAC were significantly increased 233% and 180%, respectively, in the periventricular striatum on the lesioned right side of the treated animals (Fig. 2a and 2d). However, the effects from r-metHuGDNF treatment varied in the more denervated intermediate and lateral portions of the right striatum. On the left side, HVA levels were significantly increased 72%, 70%, and 73% in the periventricular, intermediate and lateral portions of the striatum, respectively, in the r-metHuGDNF recipients (Fig. 2g-i). When compared to tissue levels in the lesioned right pallidum of vehicle recipients, dopamine, DOPAC and HVA levels were significantly increased 155%, 190% and 47%, respectively, in the right pallidum of the r-metHuGDNF recipients. Only HVA levels were significantly increased 67% in the left globus pallidus of the r-metHuGDNF recipients.

As seen in the vehicle recipients, the direct infusion of MPTP through the right carotid artery almost eliminated TH+ fibers in the right striatum, but largely spared those in the left striatum (Fig. 3a and b). While a few residual TH+ fibers could be identified at high power magnification in the right striatum of vehicle recipients (Fig. 3f and g) there was an increase in TH+ fibers in the periventricular striatal region of animals receiving infusions of r-metHuGDNF (arrows, Fig. 3h, i and j). A quantitative analysis of TH+ fibers present in the striatum revealed a five-fold increase in TH+ fiber density in the periventricular region of the right striatum compared to vehicle recipients (Fig. 4). TH+ fiber density was most evident along the ventricular border of the striatum and gradually faded in a gradient from the ventricle to deeper into the parenchyma ( $p < 0.025$ , linear regression analysis). As evident in both the photomicrographs (Fig. 3) and quantitative measurements (Fig. 4) of striatal dopamine fibers, the periventricular GDNF response ranged from moderate increases in TH+ fibers in some animals to a dense fiber network in the periventricular striatum of other monkeys. In contrast to the right striatum, there were no significant differences in fiber density between r-metHuGDNF and vehicle recipients in the left striatum.

However, the effects of r-metHuGDNF on nigral dopamine neurons were bilateral. The number of dopaminergic neurons expressing TH, was significantly increased by more than 20% on both the left side and the lesioned right side. Similarly, dopaminergic neuron perikaryal size was significantly increased by more than 30% in the left and right substantia nigra.

### **Conclusions**

The chronic infusion of 5 or 15  $\mu\text{g/day}$  r-metHuGDNF into either the lateral ventricle or the striatum of the advanced parkinsonian brain promotes restoration of the nigrostriatal dopaminergic system and significantly improves motor functions in rhesus monkeys. The behavioral improvements were as good or better than previously seen in the same model system in response to levodopa, without inducing side-effects associated with chronic levodopa administration (Myioishi *et al.*, 1997). The functional improvements were associated with a



pronounced up-regulation and regeneration of nigral dopamine neurons and their processes innervating the striatum. This was evidenced by 1) >20% bilateral increase in the number of nigral neurons expressing the dopamine marker TH, 2) >30% bilateral increase in nigral dopamine neuronal cell size, 3) >70% and >50% bilateral increase in dopamine metabolite levels in the striatum and the pallidum, 4) 233% and 155% increase in dopamine levels in the periventricular striatal region and in the globus pallidus, respectively, on the lesioned side, and 5) a five-fold increase in periventricular striatal TH+ fiber density, on the lesioned right side.

The only other chronic delivery study of GDNF in nonhuman primates has been reported by Kordower *et al.* (2000) using a lentiviral vector to transfect the GDNF gene into the striatum and substantia nigra of aged and parkinsonian rhesus monkeys. They interpreted their results in parkinsonian animals, which were similar to ours, as demonstrating neuroprotection since GDNF was delivered one week after MPTP toxicity. However, both restorative and protective actions of GDNF may have been involved as the injury sequelae to MPTP are still unfolding in the weeks immediately after MPTP treatment (Herkenham *et al.*, 1991). The GDNF levels produced by transfected cells in their study were not clear, although striatal levels of GDNF were measurable by ELISA eight months after lentiviral GDNF delivery (Kordower *et al.*, 2000). In the present study, the results are primarily attributable to the restorative actions of GDNF, as GDNF was not administered until three months following MPTP-induced nigrostriatal injury, a time at which parkinsonian features are stably expressed (Bankiewicz *et al.*, 1983; Smith *et al.*, 1993).

In the vehicle recipients, the highest levels of dopamine fibers and dopamine were present in the periventricular region of the striatum, the area where significant dopamine fiber regeneration and increases in dopamine levels were found in the r-metHuGDNF recipients. Thus, the effect of r-metHuGDNF on the lesioned right side of the striatum occurred where surviving elements of the nigrostriatal fibers were concentrated. The actions of r-metHuGDNF in restoring

striatal dopaminergic innervation may be one of the principle components of the recovery seen in the present study.

The substantia nigra is also an important structure in regulating motor functions. Consistent with previous studies with animal models of PD (Tomac *et al.*, 1995a; Gash *et al.*, 1996), Applicants observed pronounced bilateral changes in nigral dopamine neurons from the chronic infusion of r-metHuGDNF, suggesting an effect on presumably normal nigral neurons on the non-lesioned left side. These effects, along with the bilateral increase in striatal and pallidal dopamine metabolite levels, support the widespread distribution of intracerebrally injected GDNF and are consistent with the diffusion and/or retrograde transport of GDNF from the lateral ventricle or the striatum to the substantia nigra in both rats and monkeys (Tomac *et al.*, 1995b; Lapchak *et al.*, 1998). Evidence suggests that a loss of dopaminergic phenotype precedes the death of nigral neurons in animal models of PD, resulting in quiescent or atrophic dopaminergic neurons (Bowenkamp *et al.*, 1996). Thus, a GDNF-responsive cell population that cannot be visualized using markers such as TH, might have been present and served as the target for GDNF actions within the brain.

## **Example 2: Treatment of Parkinson's Disease in humans with direct infusion of GDNF into the putamen for 24 months.**

### ***Study Design***

Five patients with idiopathic, L-dopa responsive PD who were poorly controlled on optimal medical therapy were identified. The first patient (P1) had predominantly unilateral disease affecting the left side and underwent contralateral putamenal implantation of catheter and pump for r-metHuGDNF delivery. The remaining patients (P2-5) had bilateral disease and bilateral putamenal implantations of delivery systems. The precise region of the dorsal putamen to be targeted for infusion was determined by co-localization studies

using  $^{18}\text{F}$ -dopa PET and MR images. Under MRI guidance, single-port catheters were placed into the dorsal putamen, the site of maximal loss of  $^{18}\text{F}$ -fluorodopa signal (confirmed by PET in all subjects). Pump placement and stereotactic surgery were tolerated well by all patients. However, there were some complications. P1 required perioperative repositioning of the catheter to center exactly within the dorsal putamen. This was achieved successfully on a second pass during the surgical procedure. In addition, patient 4 developed a wound infection related to the pumps and connection tubing that was successfully treated with explantation of the extracranial devices, antibiotics and re-implantation within 4 weeks.

### *Patients*

Five PD patients were included in this pilot study. Ethical approval was obtained from the local ethics committees both at Frenchay Hospital and the Hammersmith Hospitals Trusts and all participants signed full consent forms. All patients were diagnosed as suffering from idiopathic PD according to standard criteria (brain bank criteria). Patients were selected for surgery when they were suffering significant functional impairment despite optimal medical therapy. Exclusion criteria included women of child-bearing age, age over 65, the presence of clinically significant depression, or systemic disease or inability or unwillingness to comply with long-term follow-up.

### *Surgery*

Sub cortical nuclei were localized and targeted using high-resolution MR images acquired under strict stereotactic conditions. Under general anesthesia, a modified Leksell stereotactic frame was affixed parallel to the orbito-meatal plane. The anterior (AC) and posterior (PC) commissures were identified in a mid-sagittal planning scan. Axial images 2mm thick were acquired parallel to the AC-PC plane and coronal images orthogonal to these then obtained. Using magnified hard copies of the MRI scans the inversion recovery scans were overlaid with the inverted T2 images to enhance the definition of the putamenal boundaries in both

planes. Using the PET images, the area of the postero-dorsal putamen with the lowest  $^{18}\text{F}$ -dopa uptake was targeted for infusion; stereotactic target coordinates were recorded and a trajectory planned. The following day, surgery was performed under general anesthesia. Under stereotactic conditions, 1mm diameter  
5 guide tubes were implanted to a point above the putamen target over a guide rod. A 0.6 mm guide wire was introduced down the guide tube to target, following which the patients underwent repeat MR/CT imaging to verify target localization. The guide wire was then replaced with a 0.6 mm diameter catheter introduced to target. r-metHuGDNF primed SynchroMed pumps (Medtronic Inc, Minneapolis)  
10 were implanted in the upper abdominal region, subcutaneously in the first patient, and subfascially (beneath the anterior rectus sheath) in the subsequent cases; subfascial placement reduced the pump profile in the abdomen and improved cosmetic appearance. Catheters were tunneled connecting the pumps to the indwelling 0.6 mm intraparenchymal brain catheters.

15 The surgical procedure was well tolerated, with only a single-serious treatment-associated adverse event, a pericatheter and peripump infection that required antibiotic treatment and reimplantation.

### ***r-metHuGDNF Production and Infusion***

20 Recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) was prepared by Amgen Inc. This protein was produced in *Escherichia coli* cells that contain an expression plasmid with a DNA insert encoding mature human GDNF, with an addition of an amino terminal methionine. r-metHuGDNF is liquid formulated with 10 mM sodium citrate and  
25 150 mM sodium chloride at a pH of 5.0. It was supplied in single-use vials at a concentration of 10 mg/mL. Following implantation, the SynchroMed pumps were programmed to deliver a continuous infusion of 14.4  $\mu\text{g}$  of r-metHuGDNF per putamen per day at rate of 6  $\mu\text{l}$  per hour. The pumps were refilled monthly with fresh solution. The low concentration of r-metHuGDNF was maintained for a  
30 period of 8 weeks. At 2 months the pumps were refilled with fresh solution of higher concentration and programmed to deliver 43.2  $\mu\text{g}$  of

r-metHuGDNF per putamen per day at a rate of 6 µl per hour. Providing good tolerance and no side effects, this dose was to be maintained for the duration of the trial. However, due to the development of high-signal MRI changes of uncertain significance, the infusion parameters were altered to deliver lower doses (10.8 – 14.4 µg of r-metHuGDNF) at lower rates (2-6 µl per hour), in attempt to establish safe and clinically effective parameters, with repeat MRI monitoring at regular intervals. Between 12 and 18 months, all patients received a continuous infusion of 14.4 µg of r-metHuGDNF per putamen per day at rate of 6 µl per hour. At 18 months the dose of GDNF was increased to 28.8 µg per putamen per day at rate of 6 µl per hour, and remained so until 24 months except in P4 who reverted back to 14.4 µg at 20 months.

#### ***Clinical Evaluation and Follow-up***

Clinical evaluations were based on the Core Assessment Program for Intracerebral Transplantations (CAPIT)( Langston, J. W. *et al.*, 1992), a validated protocol for evaluating surgical treatments of idiopathic PD. All patients were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) and underwent timed motor tests at baseline, 3, 6, 12, 18 and 24 months. Assessments were performed in both off and on medication states. Before they were assessed off medication, patients fasted and medications were withdrawn overnight. The same assessments were then repeated after administration of L-dopa when the patients were "on".

#### ***Health-related Quality of Life Outcome Measurement and Follow-up***

Patients were also assessed using validated quality of life questionnaires: the 39-item Parkinson's Disease Questionnaire (PDQ 39) and the 36-item Medical Outcomes Study short form health survey (SF-36) were used before surgery and after 3, 6, 12, 18, and 24 months. Descriptive statistics (mean, standard deviation, range, 95% confidence interval) were obtained for each variable. Comparisons over time were made using Student's paired-samples t test.

### ***Neuropsychological Evaluation and Follow-up***

Also evaluated were changes in medication (L-dopa equivalents) requirement and neuropsychology, which contained tests of verbal intellect, verbal and visual memory, attention, executive function, anxiety and depression as has  
5 been previously described (McCarter, R. J., *et al.*, 2000). The battery of cognitive tests used was designed to minimize the possible confounding effects of both slowness of movement and movement difficulty on cognitive test results.

Friedman's Related Samples test was used to evaluate the significance of change over time in the rating scores. All analyses were performed in SPSS. Four of the  
10 patients (all of the bilateral cases) underwent pre-operative neuropsychological assessment. All five patients were assessed at 12 and 24 months post implantation. The significance of changes in cognitive test performance was evaluated using confidence intervals derived from the standard error of prediction (Lord and Novack, 1968; Atkinson, L., 1991) around the predicted true score at baseline. A  
15 significant change was inferred if a score at either 12 or 24 months fell outside of the confidence interval of the baseline score (for the unilateral case the baseline score was at 12 months and change scores were inferred for performance at 24 months). In addition, a PD control group consisting of 18 patients who had undergone other forms of surgery for PD was used to establish the effect of repeat  
20 cognitive assessment over a 12 month period. For each patient in this group two *postoperative* neuropsychological assessments were available. This control group was comparable with the GDNF patient group in terms of years of education, age at surgery, duration of PD at surgery and NART estimated FSIQ ( $p>0.05$ ).

### ***Scanning Procedures and Image Analysis***

<sup>18</sup>F-dopa PET provides a measure of synaptic amino acid decarboxylase (AADC) activity and hence acts as an *in vivo* marker of dopamine storage and the functional integrity of dopamine terminals. Previous human and animal lesion studies have demonstrated that striatal <sup>18</sup>F-dopa PET correlates with nigral cell  
30 numbers, dopamine content in striatal terminals (Garnett *et al.*, 1983; Martin *et*

*al.*, 1989; Brooks *et al.*, 1990(b); Pate *et al.*, 1993) and the UPDRS off medication (Morrish, *et al.*, 1998), in particular with the bradykinesia and rigidity sub scores (Otsuka, *et al.*, 1996). Furthermore, it is possible to demonstrate progressive decline of striatal  $^{18}\text{F}$ -dopa uptake in patients with PD over time (Morrish, *et al.*, 1998; Morrish, *et al.*, 1996).  $^{18}\text{F}$ -dopa PET was used here to assess striatal dopamine terminal function in five PD patients receiving chronic intra-striatal GDNF infusions.

The patients had  $^{18}\text{F}$ -dopa PET pre-operatively, and at 6, 12, 18, and 24 months postoperatively using an ECAT EXACT HR++ camera (CTI/Siemens 966; Knoxville, TN) in 3D acquisition mode following withdrawal from medication for at least 12 hours. Patients received 150 mg of carbidopa and 400 mg of entacapone; 1 hour later 111MBq of  $^{18}\text{F}$ -dopa in normal saline was administered as an intravenous bolus at the start of scanning. The images were acquired in 3D mode as 26 time frames over 94.5 minutes (1 x 30 seconds, 4x 1min, 3x 2min, 3x 3min and 15 x 5 mins). Parametric images of  $^{18}\text{F}$ -dopa influx constants ( $K_i$ ) were generated from time frames 25.5 to 94.5 minutes post injection using in house software (Brooks, D. J. *et al.*, 1990; Rakshi, J. S. *et al.*, 1999) based on the MTGA approach of Patlak and Blasberg (Patlak, C. S. & Blasberg, R. G., 1985)). Occipital counts from the same time frames were used to generate the tissue reference input function. Integrated images (time frames 25.5-94.5) were used to identify the parameters required to transform the  $K_i$  images into standard stereotaxic MNI space. The transformation matrix was then applied to the  $K_i$  images. After normalization a gaussian filter (6 x 6 x 6 mm) was applied. Mean voxel values of the normalized  $K_i$  images were compared throughout the midbrain and basal ganglia at baseline, 6, and 12 months postoperatively using a paired-Student's t-test in SPM99 after application of a mask to eliminate cortical signals and so reduce the number of statistical comparisons. Any regional increases in  $^{18}\text{F}$ -dopa uptake could subsequently be defined as a volume of interest and the mean  $K_i$  values for those volumes extracted using the appropriate SPM tool (Brett, M., *et al.*, 2002).

The integrated images were subsequently co-registered to each patient's MRI scan for region of interest (ROI) analysis. All MRIs had been previously reformatted in the AC-PC plane. The subsequent transformation matrix was then applied to individual Ki images in order to transform them into the individual MRI space. Regions of interest (ROIs) were traced on the MRI and included the head of the caudate and the dorsal putamen which was divided into anterior and posterior halves. The position of the catheter tip was also calculated relative to the AC-PC line and an oval region of interest (6 mm x 12 mm) centred at the tip location in the axial plane. The ROI was then copied onto 2 planes either side of the slice containing the calculated tip location, creating a 12 mm x 6 mm x 5 mm (0.36 cc) volume of interest centered on the catheter tip. The regions of interest were then used to sample  $^{18}\text{F}$  activity on the parametric image. In the 4 patients operated on bilaterally, the mean Ki values for the left and right regions of interest were averaged to produce one Ki value for each of the five ROIs per scan. Only the ROIs from the operated right side of the patient who received unilateral surgery were included in the analyses. The patient's Ki values were then subjected to a paired Student's two-tailed t test.

#### ***Lack of adverse effects of r-metHuGDNF infusion***

Surprisingly, side effects due to r-metHuGDNF infusion itself were very limited. There was no nausea, anorexia, vomiting or weight loss reported as in the previous intraventricular trial (Kordower, J. H. *et al.*, 1999). There were no haematological or blood chemistry abnormalities. At the high dose (43.2  $\mu\text{g}$ /putamen/day), 3 subjects reported abnormalities of taste and smell (soapy or metallic), 2 subjects reported that their dreams had become abnormally vivid, and 4 subjects described a Lhermitte's phenomenon (tingling passing from the neck down through the arms and sometimes onto the trunk and down the legs provoked by neck flexion). None of these effects necessitated immediate dose cessation or reduction, and all remitted (except for occasional, mild Lhermitte's sign) after the dose change discussed below that was instituted after the appearance of a high-density signal on MRI (end of month 3). The Lhermitte's



events were mild, intermittent, non-distressing; and most frequently occurred at the higher dose; and in fact it was often described as “pleasurable”.

In all patients, T2 MR images showed a region of high-signal intensity around the tips of the catheters. This response varied between patients, and even  
5 between the two hemispheres in bilaterally implanted cases. The signal change was most evident following the dose escalation of r-metHuGDNF. Uncertainty as to the relevance of these changes, led to a reduction of r-metHuGDNF delivery back to 14.4 µg/putamen/day for all patients between 3 and 6 months that resulted in a substantial reduction of the high signal.

10

### ***Efficacy of r-metHuGDNF infusion***

Improvement in patients’ parkinsonian symptoms and signs were evident within 3 months of commencing the infusion and continued to improve throughout the study. Patient diaries revealed that periods of severe immobility,  
15 one of the cardinal features of PD that occupied approximately 20% of the waking day prior to surgery, were eliminated completely by 6 months of r-metHuGDNF infusion. At 24-months dyskinesias were reduced significantly by 73% in duration ( $p<0.05$ ) and were all reported as mild in nature (Table 3). We observed mild dyskinesias in the practically defined off state in P4, who additionally  
20 reported short-lived infrequent early morning occurrences. These changes were not due to increases in medication. The study protocol aimed to maintain medication unchanged throughout the first year of r-metHuGDNF treatment. However, P3 had been taking medication on demand due to frequent periods of akinesia at the onset of the study, and needed to reduce his medication as his  
25 symptoms improved (Table 7). Patient P5 had increased sensitivity to L-dopa after GDNF infusion and also needed to reduce his dosage. The other 3 patients needed slight increases in their L-dopa equivalents intake. At 24 months, the mean daily dose of L-dopa equivalents was reduced by 26% (based on a formula as designated by Pahwa, et al., (1997)).

30

The most widely used and validated scale for assessing functional changes in PD is the Unified Parkinson’s Disease Rating Scale (UPDRS). In all patients,

the rate of symptomatic improvement was maximal in the first 3 months of GDNF infusion and, thereafter, there was slower but sustained improvement throughout the entire 24 months of follow-up. The total UPDRS scores in the clinically defined "off" phase when assessed 12 months following commencement of r-metHuGDNF infusion showed a reduction from baseline of 48% and (Fig. 6a). Although this was a small group of patients, we performed a non-parametric significance test, which showed that this reduction was highly significant across the three time points ( $P < 0.005$ ; Friedman test). The largest effects were seen over the first three months, but the effect persisted throughout the trial. There was also a 45% reduction in total UPDRS scores in the clinically defined "on" phase by 12 months, which followed a similar pattern over time ( $P < 0.002$ ; Friedman test; Fig. 6a). Although P4's final score was still below baseline (Fig. 6a), he did show a worsening of symptoms at the twelve-month assessment; this may have been due to an unrelated inter-current infection.

The patients experienced a mean 41% ( $p < 0.001$ ) improvement in 'off-period' total UPDRS over the first 12 months of follow-up. When the results were broken down, it was clear that these effects in total UPDRS during the "off" phase were reflected by improvements in both activities of daily living (ADL) UPDRS subscale II ( $P < 0.002$ ; Friedman test; Fig. 6a) and motor UPDRS subscale III scores ( $P < 0.002$ ; Friedman test; Fig. 6a). The patients experienced a mean 44% ( $p < 0.0001$ ) improvement in 'off-period' part III motor UPDRS score.

The symptomatic effect at 18-months showed some deterioration from 12 months so the GDNF infusion dose was increased. At 24 months, there was progressive benefit in comparison to 12 months, with the scores in the off-medication state tending towards the baseline best on-medication state. The overall UPDRS scores progressively improved by 57% ( $p < 0.005$ ) and 52% ( $p < 0.005$ ) in both the off and on medication states respectively (Fig. 6a,b). The effect of 24 month GDNF infusion on the patients' motor performance (UPDRS part III) was significant in both the off and on medication states, resulting in a 57% ( $p < 0.001$ ) and 48% ( $p < 0.01$ ) score reduction, respectively (Fig. 6b). There was significant improvement in the patients' functional performance with GDNF

infusion, as demonstrated by activities of daily living scores (UPDRS part II), which at 24 months were reduced by 63% ( $p < 0.005$ ) and 58% ( $P < 0.05$ ) in the off and on medication states respectively (Fig. 6b).

Involuntary movements (i.e. dyskinesias) are a common problem in PD and were suffered by all but one of the patients at the start of the trial. The overall dyskinesia scores (UPDRS subscale IVa) were significantly reduced on medication following r-metHuGDNF infusion for 12 months ( $P < 0.01$ ; Friedman test). No dyskinesias were seen in these patients when off medication. Timed motor tests were assessed and followed the protocol outlined by the Core Assessment Program for Intracerebral Transplantation (CAPIT) (Langston, J. W. *et al.*, 1992). These were also improved in both the “off” and “on” medication states. All the timed motor tests showed significant improvements with GDNF infusion in the off medication state (Fig. 6a, b). One patient was unable to complete the stand-walk test without multiple freezing episodes and support whilst in the off medication state preoperatively, but was able to accomplish the task without freezing and support after 12 months of GDNF infusion whilst in the off medication state. Long-term infusion resulted in progressively improved scores for akinesia, rigidity and tremor, impairment of arising from chair, gait and postural instability, when patients were evaluated off medication. GDNF infusion reduced levodopa-induced dyskinesias and motor fluctuations based on complications of therapy scores (UPDRS part IV), which at 24 months were improved by 60% and 29% respectively (Fig. 6b).

#### ***Effect of GDNF infusion on quality of life measures***

The functional status of the patients was assessed using the Parkinson's Disease Questionnaire (PDQ-39) (Peto, V., 1995) and the 36-item Medical Outcomes Study short form health survey (SF-36) before surgery and after 3, 6, 12, 18, and 24 months. All PDQ-39 domains showed improvement over time. At baseline, the scores were similar to a control PD population with moderate disease (Hoehn and Yahr III) and at 12 and 24 months these scores tended towards

a control population with mild disease (Hoehn and Yahr I) (Fig. 5a). At 12 months all dimensions were improved, with bodily discomfort significantly improved ( $p < 0.05$ ). At 24 months all dimensions except social support were improved, with significant improvements for activities of daily living, stigma and cognition ( $p < 0.05$ ) (Fig. 5a). All SF-36 domains were improved at both 12 and 24 months. With time the scores improved towards those for an age-matched healthy population (Fig. 5b). At 12 months scores for physical functioning and vitality were significantly improved ( $p < 0.05$ ) (Fig. 5b).

### *Effect of GDNF infusion on neuropsychological measures*

The test-retest performance of the PD control group over a 12 month period was assessed using repeated measures 't' tests. No significant improvement in test performance was observed. Significant declines in mean test performance over the 12 month period were observed for the arithmetic subtest of the WAIS-R, immediate and delayed recall of a short story, RAVLT learning and the number of errors obtained on the Tower of London test.

Using the 90% confidence interval of each GDNF patient's baseline score it was found that the majority of patient test scores remain unchanged both at 12 and 24 months. At 12 months there were, however, two significantly improved test scores at the 90% confidence level, one on VIQ and the other on RAVLT learning. These declines occurred in different patients. In addition at 12 months there were two significantly improved test scores, one on VIQ and the other on the delayed recall of a story. Again these significant changes occurred in two different patients. At 24 months there were more significant positive changes in test performance than at 12 months. As with 12 months there were also two test scores that declined, one on VIQ and the other on RAVLT learning. Again these declines occurred in two different patients. The declined VIQ at 24 months was in the same patient who demonstrated a significant decline at 12 months.

The significant improvements in test performance at 24 months occurred on VIQ, immediate and delayed short story recall, RAVLT learning and short

delayed recall of the RAVLT. Many of these significant improvements were also evident at the 95% confidence interval. Of these changes improvement in the immediate and delayed recall of a story occurred in one patient and improvement in delayed recall of a story in another patient. One patient demonstrated an improvement in VIQ. Two patients demonstrated an improvement in RAVLT learning with one demonstrating an improvement additionally at the short delayed recall of the RAVLT.

### *<sup>18</sup>F-dopa PET scan changes*

Positron emission tomography (PET) scans of <sup>18</sup>F-dopa uptake gives a direct indication of dopamine storage within the brain, and has been used extensively to assess dopamine changes in PD (Morrish, P. K., *et al.*, 1996). Baseline scans revealed that the posterior segment of the putamen in all patients had low <sup>18</sup>F-dopa uptake. These regions of reduced dopamine storage were used to establish the optimal site for placing the catheters for r-metHuGDNF delivery. At 6 months r-metHuGDNF was shown to increase <sup>18</sup>F-dopa uptake by 24.5% (0-49%) within a 0.36cc ovoid volume around the tip of each catheter. At 12 and 18 months post r-metHuGDNF infusion the same analysis also revealed increases in <sup>18</sup>F-dopa uptake. However, this was complicated by the fact that patient 2 moved considerably during the third scan at 12 months which may have resulted in an under estimate of his true <sup>18</sup>F-dopa uptake. The <sup>18</sup>F-dopa increases at 18 months were significant using a Student's two-tailed t-test in regions where such increases were hypothesized (P=0.021).

Although interrogating a single volume around the tip of each catheter may reveal local changes in <sup>18</sup>F-dopa uptake, changes elsewhere in the putamen or in the midbrain would be missed using this technique. Statistical parametric mapping (SPM) localizes significant changes in <sup>18</sup>F-dopa storage between scans throughout the brain and has recently been shown to be a useful method for detecting changes in dopaminergic function (Brooks, D. J. *et al.*, 1990; Rakshi, J. S. *et al.*, 1999) and for following the progression of PD (Whone, A. L. *et al.*, 2002). When the preoperative and 6 month Ki images were interrogated with

SPM three regions demonstrated focal increases in  $^{18}\text{F}$ -dopa uptake— (i) right posterior dorsal putamen (+17.9%), (ii) left medial dorsal putamen (+25.3%) and (iii) right substantia nigra (+16%). The exact locations of the regions with increased  $^{18}\text{F}$ -dopa uptake were identified with SPM superimposed on a mean MRI template constructed from the individual T1 weighted MRIs of the 5 patients. The movement of patient 2 during the 12 month scan again made interpretation of this small sample very difficult. Despite this, the patients as a group continued to demonstrate a significant increase in  $^{18}\text{F}$ -dopa within the right substantia nigra region (+26%; paired t test;  $P < 0.05$  uncorrected at cluster level).

#### ***$^{18}\text{F}$ -dopa PET: Region of Interest Analysis***

Repeated measures analysis of variance (MANOVA) identified a significant difference in the  $^{18}\text{F}$ -dopa uptake constant ( $K_i$ ) between the baseline scan and all post-operative scans in the posterior putamen ( $p < 0.001$ ). The increase was most marked at 24 months (60%,  $p < 0.001$ ). A *post-hoc* comparison of the post-operative  $K_i$  values using the Tukey-Kramer multiple comparisons test demonstrated significantly higher  $^{18}\text{F}$ -dopa uptake at 24 months than at 6, 12 and 18 months in the posterior putamen ( $p < 0.001$  for 6 months vs. 24 months,  $p < 0.05$  for 12 months vs. 24 months,  $p < 0.01$  for 18 months vs. 24 months). Limiting the region of interest to the volume of putamen surrounding the catheter tip produced similar results but with a greater percentage increase in  $^{18}\text{F}$ -dopa uptake (83% at 24 months). Repeated measures analysis of variance also identified a significant difference in  $^{18}\text{F}$ -dopa uptake in the whole putamen ( $p = 0.0237$ ), the *post-hoc* analysis however was only able to identify a significant increase between baseline and 24 months. We were unable to identify any significant change in  $^{18}\text{F}$ -dopa uptake in either the head of caudate or the anterior half of dorsal putamen over the course of this study.

***<sup>18</sup>F-dopa PET: SPM***

Pre-op and 24 month post surgery images of <sup>18</sup>F-dopa uptake constants (Ki maps) were interrogated with SPM99. Two regions showed significant increases in <sup>18</sup>F-dopa uptake: the left posterior dorsal putamen (p<0.0001 cluster corrected, Z score 3.01) and right posterior dorsal putamen (p<0.0001 cluster corrected, Z score 3.74). The right posterior dorsal putamen was also identified as a region of increased <sup>18</sup>F-dopa uptake, albeit at a lower level of significance, when the baseline images were compared with the 6, 12, and 18 month Ki maps. The left posterior dorsal putamen was identified by SPM99 as a region of significantly increased <sup>18</sup>F-dopa uptake when the baseline scans were compared with the 6 and 18 month Ki maps. The early SPM comparisons, i.e. baseline vs. 6 months and baseline vs. 12 months, localised a third region of increased <sup>18</sup>F-dopa uptake involving the right substantia nigra. SPM99 was unable to identify increased <sup>18</sup>F-dopa uptake in the right substantia nigra at 18 or 24 months.

***Conclusions***

Applicants show for the first time that direct intraputaminal GDNF infusion in patients with PD is safe, can be tolerated for at least two years and appears to effectively treat PD in humans. Furthermore, Applicants show for the first time that direct intraputaminal GDNF infusion in patients leads to sustained increases in dopamine uptake in the putamen. Although L-dopa equivalents were maintained in 3 of the 5 patients throughout this study, there was a significant reduction in dyskinetic movements by over 60% while on medication, and no dyskinetic movements off medication which has also been reported following intracerebral infusion of GDNF in monkeys (Miyoshi, Y. *et al.* (1997)). This result is in contrast to recent fetal transplant trials where some patients experience dyskinesias of unknown origin when off medication (Freed, C. *et al.*, 2001; Hagell, P. *et al.*, 2002). This finding is of major significance and a surprising benefit for PD patients and suggests that GDNF may act to regulate dopamine production, release and metabolism within the striatum thus allowing for a more physiological processing of motor output. Thus, PD patients administered GDNF directly to

the putamen experience a far better quality "on" time than ever reported previously.

The overall 57% reductions in "off" UPDRS scores after 24 months of treatment are surprisingly dramatic. The improvements were progressive, with the  
5 "off" period scores at 12 months tending closely towards the baseline best "on" period scores. A decline in most CAPIT timed tests adds further evidence substantiating an overall subjective improvement. The finding of significant reductions in the UPDRS scores in the "on" clinical phase to 52% of baseline is unprecedented. No such improvement in the "on" state following surgical  
10 treatment for PD (The Deep-Brain Stimulation for Parkinson's Disease Study Group., *New England Journal Medicine* 345, 956-963, 2001) or following transplantation of fetal dopamine neurons (Lindvall, O. & Hagell, P., 2000) has previously been reported.

PD is also often associated with impaired olfaction (Quinn, N. P. *et al.*,  
15 1987) assumed to be the result of Lewy bodies in the olfactory bulb and cortex (Daniel, S. E. *et al.*, 1992). In fact, three patients had long-standing loss of sensation of smell and taste, as is often the case in PD. Surprisingly, three patients reported a return of sense of smell following r-metHuGDNF infusion. These symptoms greatly improved or resolved completely between 3 and 6 weeks of  
20 r-metHuGDNF infusion (Table 7). However, with this recovery, abnormal sensations of taste were intermittently experienced, with "metallic" or "soapy" tastes being reported.

At the highest dose of r-metHuGDNF, three patients also reported recovery of normal sexual function, both in terms of interest and potency. This  
25 recovery subsided as the dose was reduced.

The patients' functional performance was improved with infusion, as demonstrated by significant improvements in the activities of daily living scores (UPDRS part II and PDQ-39 ADL dimension).

It was apparent from the neuropsychological data that there was no  
30 detrimental effect of GDNF infusion on cognition. The cognitive test results in



fact provide evidence of an improvement in verbal anterograde memory function in some patients after 24 months of GDNF infusion. The finding of improved memory function at 24 months was not attributable to practice. The comparable control group of 18 PD patients did not show a significant improvement in memory function after an interval of 12 months and in fact demonstrated significant declines on a number of measures of verbal anterograde memory function. It is also unlikely that the observed improvement in memory function is attributable to statistical false positive error. Out of the 54 statistical tests conducted one would expect 5 significant results by chance alone (with  $p=0.1$ ). At 24 months there were, however, nine significant changes observed, two in the negative direction and seven in the positive direction. Of the positive changes observed six were on measures of anterograde verbal memory function.

In addition to clinical improvements, the continuous infusion of r-methHuGDNF was associated with surprisingly dramatic increases in total putamen  $^{18}\text{F}$ -dopa uptake capacity. Previous studies have estimated the annual decline in putamen  $^{18}\text{F}$ -dopa uptake to be around 10% of the baseline value in PD patients (Morrish, P. K., *et al.*, 1996; Wenning, G. K. *et al.*, 1997). In contrast, we report a 23.5% increase in total putamen  $^{18}\text{F}$ -dopa uptake following a two year infusion of GDNF into the posterior putamen. The increase in total putaminal  $^{18}\text{F}$ -dopa uptake and storage was entirely due to increases in the posterior half of the putamen or, more specifically, the putamen adjacent to the catheter tip (60% and 83%, respectively ( $p<0.01$ )). In contrast, there was only a 6.8% increase in  $^{18}\text{F}$ -dopa uptake in the anterior half of the putamen ( $p=.223$ ). In addition, in the patient who received GDNF unilaterally, a decline in total putamen  $^{18}\text{F}$ -dopa uptake of 7% over the course of the 2 years of follow up was detected. Thus, it is quite clear from these studies that the diffusion of GDNF in concentrations sufficient to induce significant changes in dopamine terminal function is limited. These results conflict with several previous animal studies in which the unilateral administration of GDNF to a unilaterally MPTP lesioned rhesus monkey resulted in significant increases in dopamine metabolites and nigral cell numbers on the contralateral side (Grondin, *et al.*, 2002; Gash, *et al.*, 1996). The difference

between the relatively limited spread of GDNF activity in this study and the more widespread effects of GDNF in previous studies is probably due to brain size. The rhesus monkey brain is 12-15 times smaller than the human brain. As a consequence, diffusion from one hemisphere to another involves a relatively modest distance particularly following intra-nigral administration. The limited diffusion observed in this study is consistent with one recent primate study in which aged rhesus monkeys received unilateral intra-striatal infusions of 22.5 µg of GDNF per 24 hours. This study reported a maximal diffusion distance of 11 mm from the catheter tip. The present study clearly indicates that chronic administration of GDNF to the brain must be localized precisely in order to achieve therapeutic effectiveness in humans.

Increased dopamine storage at the level of the substantia nigra suggest that either local nigral dopamine terminals or neuron cell bodies were also responding to the r-metHuGDNF delivered to putamen nerve terminals possibly via its retrograde transport while the early changes in sense of smell, and the overall reductions in UPDRS at 3 months suggests at least an initial pharmacological action of r-metHuGDNF within the putamen. This is likely, in part, to involve a direct stimulatory effect on dopamine release as shown in rodent models (Hoffman, A. F. *et al.*, 1997).

## REFERENCES

- 5     Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt, GA, Gash, D. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. *Journal of Comparative Neurology*. 461:250-261 (2003).
- 10    Arenas, E., Åkerud, P., Wong, V., Boylan, C., Persson, H., Lindsay, R.M., Altar, C.A. Effects of BDNF and NT-4/5 on striatonigral neuropeptides or nigral GABA neurons *in vivo*. *Eur. J. Neurosci.*, 8: 1707-1717 (1996).
- 15    Atkinson L. Three standard errors of measurement and the Wechsler Memory Scale - Revised. *Psychological Assessment: A journal of consulting and clinical psychology*, 3:136 -138 (1991).
- 20    Bhatia, K. P. & Marsden, C. D. The behavioural and motor consequences of focal lesions of the basal ganglia in man. *Brain*, 117 ( Pt 4), 859-876 (1994).
- 25    Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ.. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Life Sci.*, 39: 7-16 (1986).
- 30    Bensadoun J-C, Deglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in 6-OHDA model of Parkinson's disease using GDNF. *Exp. Neurol.*, 164: 15-24 (2000).
- 35    Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. *Brain Research*, 886: 82-98 (2000a).
- 40    Bjorklund A, Lindvall A. Parkinson's disease gene therapy moves towards the clinic. [Letter]. *Nature Med.*, 6: 1207-1208 (2000b).
- 45    Bowenkamp KE, David D, Lapchak PL, Henry MA, Grandholm AC, Hoffer B.J. 6-Hydroxydopamine induced the loss of the dopaminergic phenotype in substantia nigra neurons in the rat: a possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. *Exp. Brain Res.*, 111: 1-7 (1996).
- 50    Brett, M., Anton, J., Valabregue, R., & Poline, J. Region of interest analysis using an SPM toolbox. *NeuroImage*, 16 (2002).
- 55    Brooks, D. J. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system

atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. *Brain*, 113 (Pt 5) 1539-1552 (1990a).

Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.[comment]. *Annals of Neurology*, 28:547-555 (1990b).

Cass W.A. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. *J. Neurosci.*, 16: 8132-8139 (1996).

Choi-Lundberg DL, Lin Q, Chang Y-N, Chiang YL, Hay CM, Mohajeri H. Dopaminergic neurons protected from degeneration by GDNF gene therapy. *Science*, 275: 838-841 (1997).

Connor B, Kozlowski DA, Schaller T, Tillerson JL, Davidson BL, Bohn MC. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged parkinsonian rat. *Gene Therapy*, 6: 1936-1951 (1999).

Costa S, Mahmoud M, Pearce RKB, Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. *European Journal Pharmacol.*, 412: 45-50 (2001).

Daniel, S. E. & Hawkes, C. H. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. *Lancet*, 340, 186 (1992).

Emborg-Knott, ME, Domino EF. MPTP-induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. *Exp Neurol.*, 152: 214-220 (1998).

Freed C.R., Greene P.E., Breeze R.E. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. *N. Engl. J. Med.*, 344:710-719 (2001).

Förander, P., Söderström, S., Humpel, C., Strömberg, I. Chronic infusion of nerve growth factor into rat striatum increases cholinergic markers and inhibits striatal neuronal discharge rate. *European Journal of Neuroscience*, 8:1822-1832 (1996).

Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. *Nature*, 305: 137-138 (1983).

Gash DM, Zhang Z, Cass WA, Ovadia L, Simmerman L, Martin D. Morphological and functional effects of intranigally administered GDNF in normal rhesus monkeys. *J. Comp. Neurol.*, 363: 345-358 (1995).

Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L. Functional recovery in parkinsonian monkeys treated with GDNF. *Nature*, 380: 252-255 (1996).

Gash DM, Zhang Z, Gerhardt GA. Neuroprotective and neurorestorative properties of GDNF. [Review]. *Ann Neurol.*, 44: S121-S125 (1998).

Grondin R, Zhang Z, Elsberry DD, Gerhardt GA, Gash DM. Chronic intracerebral delivery of trophic factors via a programmable pump as a treatment for parkinsonism. In: Mouradian MM, editor. *Parkinson's disease: Methods and Protocols*. Totowa, New Jersey: Humana Press (2001) p. 257-267.

Grondin, R., Zhang, Z., Yi, A., et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.[comment]. *Brain*, 125: 2191-2201 (2002).

Hagell, P. Dyskinesias following neural transplantation in Parkinson's disease. *Nat. Neurosci.*, 5: 627-628 (2002).

Herkenham, M, Little MD, Bankiewicz K, Tang SC, Markey SP, Johannessen JN. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An *in vivo* autoradiographic study. *Neuroscience*, 40: 133-158 (1991).

Hoffman, A. F., van Horne, C. G., Eken, S., Hoffer, B. J., & Gerhardt, G. A. *In vivo* microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF. *Exp. Neurol.*, 147: 130-141 (1997).

Hou, J-G.G., Lin L-F.H., Mytilinenou, C., Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons *in vitro* and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. *J. Neurochem.*, 66: 74-82 (1996).

Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. *J. Neurosci. Meth.*, 96: 71-76 (2000).

Jellinger K. Overview of morphological changes in Parkinson's disease. *Adv. Neurol.* 45 (1986).

Kearns C, Gash, DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine *in vivo*. *Brain Research*, 672:104-111 (1995).

Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. *J. Neurosci.*, 20: 4686-4700 (2000).

Kirik D, Georgievska B, Rosenblad C, Bjorklund A. Delayed infusion of GDNF

promotes recovery of motor function in the partial lesion model of Parkinson's disease. *Eur. J. Neurosci.*, 13: 1589-1599 (2001).

Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiology and clinical implications. *N. Eng. J. Med.*, 318: 876-880 (1988).

Kordower JH, Palfi S, Chen E-Y, Shuang Y, Ma Y, Sendera T. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. *Ann. Neurol.*, 46: 419-424 (1999).

Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. *Science*, 290: 767-773 (2000).

Lang AE, Lozano AM. Parkinson's disease. First of two parts. [Review]. *N. Engl. J. Med.*, 339:1044-1053 (1998a).

Lang AE, Lozano AM. Parkinson's disease. Second of two parts. [Review]. *N. Engl. J. Med.*, 339: 1130-1143 (1998b).

Langston, J. W. *et al.* Core assessment program for intracerebral transplantations (CAPIT). *Mov Disord.*, 7, 2-13 (1992).

Lapchak PA, Araujo DM, Hilt DC, Jiao S, Collins F, Miyoshi Y, *et al.* Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. *Brain Res.*, 789: 9-22 (1998).

Lindner MD, Winn SR, Baetge EE, Hammang JP, Gentile FT, Doherty E, *et al.* Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. *Exp. Neurol.*, 132: 62-76 (1995).

Lindvall, O. & Hagell, P. Clinical observations after neural transplantation in Parkinson's disease. *Prog. Brain Res.*, 127: 299-320 (2000).

Lin L-F.H., Doherty D.H., Lile J.D., Bektess S., Collins F., GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science*, 260: 1130-1132 (1993).

Lin L-F.H., Zhang T.J., Collins F., Armes L.G., Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. *J. Neurochem.*, 63: 758-768 (1994).

Lord FM, Novick, M.R. Statistical theories of mental test scores. Reading, MA:

Addison-Wesley, 1968.

Ma, Y., Feigin, A., Dhawan, V., Fukuda, M., Shi, Q., Greene, P., Breeze, R., Fahn, S., Freed, C., Eidelberg, D. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study (2002).

Martin WR, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. *Annals of Neurology*, 26:535-542 (1989).

McCarter, R. J., Walton, N. H., Rowan, A. F., Gill, S. S., & Palomo, M. Cognitive functioning after subthalamic nucleotomy for refractory Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry*, 69: 60-66 (2000).

Miyoshi Y, Zhang Z, Ovadia A, Lapchak PA, Collins F, Hilt D, *et al.* Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. *Ann. Neurol.*, 42: 208-214 (1997).

Morrish, P. K., Sawle, G. V., Brooks, D. J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. *Brain*, 119 ( Pt 2), 585-591 (1996).

Morrish, P.K., Rakshi, J.S., Bailey, D.L. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.[comment]. *Journal of Neurology, Neurosurgery & Psychiatry*, 64: 314-319 (1998).

Olson, L., Nordberg, A., von Holst, H., Backman, T., Ebendal, T., Alafuzoff, I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A., Lundqvist, H., Langstrom, B., Meyerson, B., Persson, A., Viitanen, M., Winblad, B., and Seiger, A. Nerve growth factor affects <sup>11</sup>C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (Case Report). *Journal of Neural Transmission [P-D Sect]*, 4: 79-95 (1992).

Olson L. Combating Parkinson's disease—step three. [Review]. *Science*, 290: 721-724 (2000).

Otsuka, M., Ichiya, Y., Kuwabara, Y., *et al.* Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. *Journal of the Neurological Sciences*, 136: 169-173 (1996).

Ovadia A, Zhang Z, Gash DM. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. *Neurobiol. Aging*, 16: 931-937 (1995).

Pate BD, Kawamata T, Yamada T *et al.* Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. *Annals of Neurology*, 34: 331-338 (1993).

Patlak, C. S. & Blasberg, R. G. Graphical evaluation of blood-to-brain transfer

constants from multiple- time uptake data. Generalizations. *J. Cereb. Blood Flow Metab.* 5: 584-590 (1985).

Pahwa R, Wilkinson S, Smith D et al. High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. *Neurology*, 49: 249-253 (1997).

Peto, V., Jenkinson, C., Fitzpatrick, R., & Greenhall, R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. *Qual. Life Res.*, 4: 241-248 (1995).

Quinn, N. P., Rossor, M. N., & Marsden, C. D. Olfactory threshold in Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry*, 50: 88-89 (1987).

Rakshi, J. S. et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. *Brain*, 122 ( Pt 9): 1637-1650 (1999).

Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastratial glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. *Neuroscience*, 82: 129-137 (1998).

Smith RD, Zhang Z, Kurlan R, McDermott M, Gash DM. Developing a stable bilateral model of parkinsonism in rhesus monkeys. *Neuroscience*, 52: 7-16 (1993).

Smith Y, Kieval JZ. Anatomy of the dopamine system in the basal ganglia. [Review]. *Trends Neurosci.*, 23(Suppl): S28-S33 (2000).

The Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep brain stimulation of the subthalamic nucleus or the pars interna of the globus palidus in Parkinson's Disease. *New England Journal Medicine*, 345: 956-963 (2001).

Tomac A, Lindqvist E, Lin L-FH, Ogren SO, Young D, Hoffer BJ, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF *in vivo*. *Nature*, 373: 335-339 (1995a).

Tomac A, Widenfalk, Lin L-FH, Kohno T, Ebendal T, Hoffer BJ, et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. *Proc. Natl. Acad. Sci. USA*, 92: 8274-8278 (1995b).

Wenning, G. K. et al. Short- and long-term survival and function of unilateral intrastratial dopaminergic grafts in Parkinson's disease. *Ann. Neurol.*, 42, 95-107 (1997).

Whone, A. L. et al. The REAL-PET study: Slower progression in early Parkinson's



disease treated with ropinirole compared with L-dopa. *Neurology*, **58**, A82-A83 (2002).

Zhang Z., Miyoshi Y, Lapchak PA, Collins F, Hilt D, Lebel C, *et al.* Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. *J. Pharmacol. Exp. Ther.*, 282: 1396-1401 (1997).